0001213900-12-006120.txt : 20121114 0001213900-12-006120.hdr.sgml : 20121114 20121114110136 ACCESSION NUMBER: 0001213900-12-006120 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 10 CONFORMED PERIOD OF REPORT: 20120930 FILED AS OF DATE: 20121114 DATE AS OF CHANGE: 20121114 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Neonode, Inc CENTRAL INDEX KEY: 0000087050 STANDARD INDUSTRIAL CLASSIFICATION: ELECTRONIC COMPONENTS, NEC [3679] IRS NUMBER: 941517641 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35526 FILM NUMBER: 121201803 BUSINESS ADDRESS: STREET 1: 2350 MISSION COLLEGE BLVD STREET 2: SUITE 190 CITY: SANTA CLARA STATE: CA ZIP: 95054 BUSINESS PHONE: 408 496-6722 MAIL ADDRESS: STREET 1: 2350 MISSION COLLEGE BLVD STREET 2: SUITE 190 CITY: SANTA CLARA STATE: CA ZIP: 95054 FORMER COMPANY: FORMER CONFORMED NAME: SBE INC DATE OF NAME CHANGE: 19920703 10-Q 1 f10q0912_neonode.htm QUARTERLY REPORT f10q0912_neonode.htm


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 10-Q

(Mark one)

x           Quarterly report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934

For the quarterly period ended September 30, 2012

o           Transition report pursuant to section 13 or 15(d) of the Securities and Exchange Act of 1934

For the transition period from _______ to ________

Commission file number 0-8419
 
NEONODE INC.
 
(Exact name of registrant as specified in its charter)
 
Delaware
 
 
94-1517641
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
 
2350 Mission College Blvd, Suite 190, Santa Clara, CA 95054 USA
(Address of principal executive offices and zip code)
 
(408) 496-6722
(Registrant's telephone number, including area code)
 
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Yes ý    No ¨

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).
Yes ý   No o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of “large accelerated filer”, “non-accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
 
 
Large accelerated filer o
Accelerated filer                   o
 
Non-accelerated filer   o (do not check if a smaller reporting company)
Smaller reporting company x
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.  Yes ¨   No ý

The number of shares of the registrant’s common stock outstanding as of November 9, 2012, was 33,125,319.
 
 
 

 
 
NEONODE INC.

INDEX TO SEPTEMBER 30, 2012 FORM 10-Q
 
PART I
Financial Information
 
     
Item 1
Financial Statements
3
     
 
Condensed Consolidated Balance Sheets as of September 30, 2012 (Unaudited) and December 31, 2011
3
     
 
Unaudited Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2012 and 2011
4
     
 
Unaudited Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2012 and 2011
5
     
 
Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2012 and 2011
6
     
 
Notes to Unaudited Condensed Consolidated Financial Statements
7
     
Item 2
Management's Discussion and Analysis of Financial Condition and Results of Operations
27
     
Item 3
Quantitative and Qualitative Disclosures about Market Risk
31
     
Item 4
Controls and Procedures
31
     
PART II
Other Information
 
     
Item 1
Legal Proceedings 
31
     
Item 1A
Risk Factors
32
     
Item 6
Exhibits
32
     
SIGNATURES
 
33
     
EXHIBITS
 
 
 
2

 
 
PART I.     Financial Information

Item 1.       Financial Statements
 
NEONODE INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share amounts)
 
   
September 30,
2012
   
December 31,
2011
 
ASSETS
 
(Unaudited)
       
Current assets:
           
Cash
 
$
11,246
   
$
12,940
 
Accounts receivable
   
1,526
     
3,345
 
Prepaid expenses and other current assets
   
382
     
234
 
    Total current assets
   
13,154
     
16,519
 
Property and equipment, net
   
340
     
108
 
    Total assets
 
$
13,494
   
$
16,627
 
LIABILITIES AND STOCKHOLDERS' EQUITY
               
Current liabilities:
               
Accounts payable
 
$
498
   
$
447
 
Accrued expenses
   
737
     
601
 
Deferred revenue
   
2,594
     
1,906
 
    Total current liabilities
   
3,829
     
2,954
 
    Total liabilities
   
3,829
     
2,954
 
Commitments and contingencies (Note 8)
               
                 
Stockholders' equity:
               
Series A Preferred stock, 444,541 shares authorized with par value $0.001 per share; 83 shares issued and outstanding at September 30, 2012 and December 31, 2011. (In the event of dissolution, each share of Series A Preferred stock has a liquidation preference equal to par value of $0.001 over the shares of common stock)
   
-
     
-
 
                 
Series B Preferred stock, 54,425 shares authorized with par value $0.001 per share; 95 and 114 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively. (In the event of dissolution, each share of Series B Preferred stock has a liquidation preference equal to par value of $0.001 over the shares of common stock)
   
-
     
-
 
                 
Common stock, 70,000,000 shares authorized with par value $0.001 per share; 33,125,319 and 32,778,993 shares issued and outstanding at September 30, 2012 and December 31, 2011, respectively
   
33
     
33
 
Additional paid-in capital
   
146,067
     
142,955
 
Accumulated other comprehensive income
   
52
     
13
 
Accumulated deficit
   
(136,487
)
   
(129,328
)
Total stockholders' equity
   
9,665
     
13,673
 
Total liabilities and stockholders' equity
 
$
13,494
   
$
16,627
 
 
See accompanying notes to condensed consolidated financial statements.
 
 
3

 
 
NEONODE INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

   
Three months ended September 30,
   
Nine months ended September 30,
 
   
2012
   
2011
   
2012
   
2011
 
                         
Net revenues 
  $ 1,679     $ 1,287     $ 4,817     $ 2,109  
Cost of revenues  
    337       333       1,080       726  
Gross margin   
    1,342       954       3,737       1,383  
                                 
Operating expenses:
                               
Product research and development   
    1,451       385       3,616       1,043  
Sales and marketing  
    920       411       3,437       1,126  
General and administrative  
    1,086       518       3,772       2,303  
Total operating expenses
    3,457       1,314       10,825       4,472  
Operating loss
    (2,115 )     (360 )     (7,088 )     (3,089 )
Other expense, net:
                               
Interest expense
    --       (76 )     --       (211 )
Non-cash items related to debt discounts and
                               
   deferred financing fees and the valuation of
                               
   conversion features and warrants
    --       (1,475 )     --       (11,043 )
Total other expense, net
    --       (1,551 )     --       (11,254 )
Loss before provision for income taxes
    (2,115 )     (1,911 )     (7,088 )     (14,343 )
Provision for income taxes
    29       19       71       30  
Net loss
  $ (2,144 )   $ (1,930 )   $ (7,159 )   $ (14,373 )
Loss per common share:
                               
Basic and diluted loss per share
  $ (0.06 )   $ (0.07 )   $
(0.22
)   $ (0.55 )
 Basic and diluted – weighted average shares used in per share
    computations    
    33,021       27,934      
32,934
      26,050  

See accompanying notes to condensed consolidated financial statements.

 
4

 
NEONODE INC.
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands)
(Unaudited)
 
   
Three months ended September 30,
   
Nine months ended September 30,
 
    2012    
2011
   
2012
   
2011
 
                         
Net loss
  $ (2,144 )   $ (1,930 )   $ (7,159 )   $ (14,373 )
Other  comprehensive income (loss):
                               
Foreign currency translation adjustments
    67       (34 )     39       (16 )
Total  comprehensive loss
  $ (2,077 )   $ (1,964 )   $ (7,120 )   $ (14,389 )
 
See accompanying notes to condensed consolidated financial statements.
 
 
5

 
NEONODE INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands) (Unaudited)
 
   
Nine months ended September 30,
 
   
2012
   
2011
 
Cash flows from operating activities:
           
    Net loss    
 
$
(7,159)
   
$
(14,373)
 
Adjustments to reconcile net loss to net cash used in operating activities:
               
    Stock-based compensation expense
   
2,957
     
517 
 
    Depreciation and amortization 
   
 68
     
17
 
    Debt discounts and deferred financing fees and the valuation of conversion
               
        features and warrants 
   
--
     
11,043
 
    Changes in operating assets and liabilities:
               
    Accounts receivable  
   
1,841
     
(450
    Prepaid expenses 
   
(135
   
(12)
 
    Accounts payable and accrued expenses
   
138
     
(205)
 
    Deferred revenue 
   
688
     
2,038
 
    Net cash used in operating activities
   
(1,602
)
   
(1,425
)
Cash flows from investing activities:
               
    Purchase of property and equipment 
   
       (290
   
(59
)
    Net cash used in investing activities 
   
 (290
   
(59
)
Cash flows from financing activities:
               
    Proceeds from issuance of convertible debt 
   
--
     
4,228
 
    Repayment of convertible debt 
   
--
     
(25
    Proceeds from exercise of warrants  
   
155
     
515
 
    Net cash provided by financing activities 
   
155
     
4,718
 
Effect of exchange rate changes on cash 
   
43
     
1
 
                 
Net (decrease) increase in cash
   
 (1,694
   
3,235
 
Cash at beginning of period  
   
12,940
     
911
 
Cash at end of period
 
$
11,246
   
$
4,146
 
Supplemental disclosure of cash flow information:
               
Cash paid during the period for:
               
    Interest paid
 
$
--
   
$
90
 
    Income taxes paid
 
$
          71
   
$
4
 
                 
Supplemental disclosure of non-cash transactions:
               
Debt discount recorded as part of convertible debt financing
               
transactions including, warrants issued
 
$
-
   
$
4,228
 
Debt issuance costs related to 2011 financing
 
$
  --
   
35
 
Accrued expenses converted to common stock
 
$
--
   
$
120
 
Conversion of debt and accrued interest to common stock
 
$
--
   
$
2,860
 
Reduction of derivative liabilities upon conversion of debt
 
--
   
13,379
 
 
See accompanying notes to condensed consolidated financial statements

 
6

 

NEONODE INC.
Notes to the Condensed Consolidated Financial Statements
(Unaudited)

1. Interim Period Reporting
 
The unaudited interim condensed consolidated financial statements, include all adjustments, consisting of normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the financial position and results of operations and cash flows for the interim periods. The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of expected results for the full 2012 fiscal year.
 
The accompanying condensed consolidated financial statements as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 have been prepared by us, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally contained in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted.  These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes contained in our consolidated financial statements and the notes thereto for the fiscal year ended December 31, 2011.

Operations
 
Neonode Inc., “we”, “us”, “our”, the “Company”, develops and licenses MultiSensing TM touch user interfaces and optical multi-touch solutions. The cornerstone of our interface solutions is zForce®, our patented touch technology. Neonode licenses the Neonode MultiSensing TM touch technology to Original Equipment Manufacturers (“OEMs”) and Original Design Manufacturers (“ODMs”) who embed our technology into devices that they produce and sell. Our solution is currently being integrated into products such as mobile phones, e-Readers and tablets, printers and office equipment, toys and gaming consoles, automotive and in-vehicle infotainment systems.
 
 Intellectual Property
 
We rely on a combination of intellectual property laws, as well as confidentiality procedures and contractual provisions, to protect our proprietary technology and our brand. We have registered, and applied for the registration of, U.S. and international trademarks, service marks, domain names, and copyrights. Additionally, we have filed U.S. and international patent applications covering certain of our proprietary technology. Over time, we have assembled a portfolio of patents, trademarks, service marks, copyrights, domain names, and trade secrets covering our products and services. Our proprietary technology is not dependent on any single patent or copyright or groups of related patents or copyrights. We believe the duration of our patents is adequate relative to the expected lives of our products. Although we rigorously protect our proprietary technology, any significant impairment of, or third-party claim against, our intellectual property rights could harm our business or our ability to compete.

2. Summary of Significant Accounting Policies
 
Fiscal Year
 
Our fiscal year is the calendar year.

Principles of Consolidation

The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include the accounts of Neonode Inc. and its wholly owned Swedish subsidiary, Neonode Technologies AB. All inter-company accounts and transactions have been eliminated in consolidation.
         
 
7

 
 
Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires making estimates and assumptions that affect, at the date of the financial statements, the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates include, but are not limited to, collectability of accounts receivable, recoverability of long-lived assets, the valuation allowance related to our deferred tax assets and the fair value of securities, such as options and warrants issued for stock-based compensation.

Cash

We have not had any liquid investments other than normal cash deposits with bank institutions to date.  If in the future the Company purchases cash equivalents, the Company will consider all highly liquid investments with original maturities of three months of less to be cash equivalents.
 
Concentration of Cash Balance Risks
 
Cash balances are maintained at various banks in the U.S. and Sweden. At times, deposits held with financial institutions in the United States of America may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation (“FDIC”), which provides basic deposit coverage with limits up to $250,000 per owner. In addition to the basic insurance deposit coverage, the FDIC is providing temporary unlimited coverage for noninterest bearing transaction accounts through December 31, 2012. The Swedish government provides insurance coverage up to 100,000 Euro per customer and covers deposits in all types of accounts. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to the deposits. As of September 30, 2012, the Company has approximately $10.8 million in excess of insurance limits.

Accounts Receivable and Allowance for Doubtful Accounts  

Our accounts receivable are stated at net realizable value. Our policy is to maintain allowances for estimated losses resulting from the inability of our customers to make required payments. Credit limits are established through a process of reviewing the financial history and stability of each customer. Where appropriate, we obtain credit rating reports and financial statements of the customer when determining or modifying its credit limits. We regularly evaluate the collectability of our trade receivable balances based on a combination of factors. When a customer’s account balance becomes past due, we initiate dialogue with the customer to determine the cause. If it is determined that the customer will be unable to meet its financial obligation, such as in the case of a bankruptcy filing, deterioration in the customer’s operating results or financial position or other material events impacting its business, we record a specific allowance to reduce the related receivable to the amount we expect to recover. Should all efforts fail to recover the related receivable, we will write-off the account. We also record an allowance for all customers based on certain other factors including the length of time the receivables are past due and historical collection experience with customers.  We determined that an allowance for doubtful accounts was not necessary at September 30, 2012 or December 31, 2011.

Debt Issuance Costs

Debt issuance costs represent costs incurred in connection with the issuance of the convertible notes payable. Debt issuance costs are amortized over the term of the financing instrument on a straight-line basis, which approximates the effective interest method.

 
8

 
 
Property and Equipment

Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method based upon estimated useful lives of the assets ranging from three to five years as follows:

Computer equipment
3 years
Furniture and fixtures
5 years

Equipment purchased under capital leases is amortized on a straight-line basis over the estimated useful life of the asset or the term of the lease, whichever is shorter.
 
Upon retirement or sale of property and equipment, cost and accumulated depreciation and amortization are removed from the accounts and any gains or losses are reflected in the consolidated statement of operations. Maintenance and repairs are charged to expense as incurred.
 
Long-lived Assets

We assess any impairment by estimating the future cash flow from the associated asset in accordance with relevant accounting guidance. If the estimated undiscounted future cash flow related to these assets decreases or the useful life is shorter than originally estimated, we may incur charges for impairment of these assets.  At September 30, 2012, we believe there is no impairment of our long-lived assets. There can be no assurance, however, that market conditions will not change or sufficient commercial demand for our products and services will materialize, which could result in impairment of long-lived assets in the future.

             Foreign Currency Translation and Transaction Gains and Losses

The functional currency of our foreign subsidiary is the applicable local currency, the Swedish Krona. The translation from Swedish Krona to U.S. Dollars is performed for balance sheet accounts using current exchange rates in effect at the balance sheet date and for income statement accounts using a weighted-average exchange rate during the period. Gains or losses resulting from translation are included as a separate component of accumulated other comprehensive income (loss). Gains or (losses) resulting from foreign currency transactions are included in general and administrative expense in the accompanying condensed consolidated statements of operations and were $71,000 and $41,000 during the three months ended September 30, 2012 and 2011, respectively, and $82,000 and $(16,000) during the nine months ended September 30, 2012 and 2011, respectively. Foreign currency translation gain (loss) was $67,000 and $(34,000) for the three months ended September 30, 2012 and 2011, respectively, and was $39,000 and $(16,000) for the nine months ended September 30, 2012 and 2011, respectively.

Liability for Warrants and Embedded Derivatives  

We do not enter into derivative contracts for purposes of risk management or speculation.  However, from time to time, we enter into contracts that are not considered derivative financial instruments in their entirety but that include embedded derivative features, such as conversion features. Such embedded derivatives are assessed at inception of the contract and every reporting period, depending on their characteristics, are accounted for as separate derivative financial instruments pursuant to accounting guidance, if such embedded conversion features, if freestanding, would meet the classification of a liability. Accounting guidance requires that we analyze all material contracts and determine whether or not they contain embedded derivatives. Any such embedded conversion features that meet the above criteria are then bifurcated from their host contract and recorded on the consolidated balance sheet at fair value and the changes in the fair value of these derivatives are recorded each period in the consolidated statements of operations as an increase or decrease to non-cash charges for conversion features and warrants.
 
 
9

 
 
Similarly, if warrants meet the criteria in accordance with accounting guidance to be classified as liabilities, then the fair value of the warrants are recorded on the consolidated balance sheet at their fair values, and any changes in such fair values are recorded each period in the consolidated statements of operations as an increase or decrease to non-cash charges for conversion features.
 
On December 14, 2011, all of the outstanding convertible debt and accrued interest was paid or converted into shares of the Company’s common stock. As of December 31, 2011, the fair value of the embedded conversion features was $0.
 
Concentration of Credit and Business Risks
 
In the short term, we anticipate that we will depend on a limited number of customers for substantially all of our future revenue. Failure to anticipate or respond adequately to technological developments in our industry, changes in customer or supplier requirements or changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of products or services, could have a material adverse effect on our business, operating results and cash flows.
 
Our accounts receivable as of September 30, 2012 was due from eleven customers, three of which accounted for 77% of our accounts receivable as of September 30, 2012.

Our net revenues for the three months ended September 30, 2012 was earned from nine customers. Our customers are located in the U.S., Europe and Asia. Customers who accounted for 10% or more of our net revenues during the three months ended September 30, 2012 are as follows:

      
Amazon - 31%
      
Kobo - 27%
      
Sony Corporation - 18%
      
Barnes & Noble – 13%

Our net revenues for the nine months ended September 30, 2012 was earned from eighteen customers. Customers who accounted for 10% or more of our net revenues during the nine months ended September 30, 2012 are as follows:

      
Amazon  - 46%
      
Kobo – 16%
      
Sony Corporation – 14%

Our accounts receivable as of December 31, 2011 was due from five customers, two of which accounted for 87% of our accounts receivable as of December 31, 2011. Our net revenues for the three months ended September 30, 2011 was earned from six customers, three of which accounted for approximately 94% of our total net revenues for the three months ended September 30, 2011. Our net revenues for the nine months ended September 30, 2011 was earned from eight customers, three of which accounted for approximately 89% of our net revenues for the nine months ended September 30, 2011.
 
Risks and Uncertainties

Our long-term success is dependent on our obtaining sufficient capital to fund our operations and to develop our products, and on our bringing such products to the worldwide market and obtaining sufficient sales volume to be profitable. To achieve these objectives, we may be required to raise additional capital through public or private financings or other arrangements. It cannot be assured that such financings will be available on terms attractive to us, if at all. Such financings may be dilutive to our stockholders and may contain restrictive covenants.

We are subject to certain risks common to technology-based companies in similar stages of development. Principal risks include risks relating to the uncertainty of market acceptance for our products, a history of losses since inception, our ability to remain competitive in response to new technologies, the costs to defend, as well as risks of losing patents and intellectual property rights, on our future customers ability to develop and sell products that incorporate our technology, the concentration of our operations in a limited number of facilities, the uncertainty of demand for our products in certain markets, our ability to manage growth effectively, our dependence on key members of our management and development team, our limited experience in conducting operations internationally, and our ability to obtain adequate capital to fund future operations.
 
 
10

 
 
We are exposed to a number of economic and industry factors that could result in portions of our technology becoming obsolete or not gaining market acceptance. These factors include, but are not limited to, technological changes in our markets, our ability to meet changing customer requirements, competitive pressures in products and prices, and the ability of our customers to manufacture and sell their products that incorporate our technology.

A significant portion of our business is conducted in currencies other than the U.S. dollar (the currency in which the Company’s financial statements are reported), primarily the Swedish Krona and, to a lesser extent, the Euro. We incur a significant portion of our expenses in Swedish Krona, including a significant portion of our product development expenses and a substantial portion of our general and administrative expenses. As a result, appreciation of the value of the Swedish Krona relative to the other currencies, particularly the U.S. dollar, could adversely affect operating results. We do not currently undertake hedging transactions to cover our currency exposure, but we may choose to hedge a portion of our currency exposure in the future as deemed appropriate.

Our future success depends on market acceptance of our technology as well as our ability to introduce new versions of our technology to meet the evolving needs of our customers.

Revenue Recognition

Engineering Services:

We may sell engineering consulting services to our customers on a flat rate or hourly rate basis. We recognize revenue from these services when all of the following conditions are met: (1) evidence existed of an arrangement with the customer, typically consisting of a purchase order or contract; (2) our services were performed and risk of loss passed to the customer; (3) we completed all of the necessary terms of the contract; (4) the amount of revenue to which we were entitled was fixed or determinable; and (5) we believed it was probable that we would be able to collect the amount due from the customer. To the extent that one or more of these conditions has not been satisfied, we defer recognition of revenue.  Generally, we recognize revenue as the engineering services stipulated under the contact are completed and accepted by our customers.  
   
Licensing Revenues:

We also derive revenue from the licensing of internally developed intellectual property (“IP”). We enter into IP licensing agreements that generally provide licensees the right to incorporate our IP components in their products with terms and conditions that vary by licensee. The IP licensing agreements generally include a nonexclusive license for the underlying IP. Fees under these agreements may include license fees relating to our IP and royalties payable following the sale by our licensees of products incorporating the licensed technology. The license for our IP has standalone value and can be used by the licensee without maintenance and support. As of September 30, 2011, Neonode meets all the accounting requirements for revenue recognition as per unit royalty products are distributed or licensed by the Company’s customers.   For technology license arrangements that do not require significant modification or customization of the underlying technology, we recognize new technology license revenue when: (1) we enter into a legally binding arrangement with a customer for the license of technology; (2) customer distributes or license the products; (3) customer payment is deemed fixed or determinable and free of contingencies or significant uncertainties; and (4) collection is reasonably assured.
 
Prior to September 30, 2011, we deferred the technology license fee revenue until such time as the warranty period stipulated in the license agreement expired because we did not have sufficient historical experience in estimating potential warranty costs.  From June 2010 to September 30, 2011, we entered into 12 technology license contracts with customers.  During that time there were no warranty related costs incurred for any customer products after they have been released to market.  During the quarter ended September 30, 2011, the Company performed an analysis and determined that it had sufficient historical evidence regarding estimated warranty costs and therefore began recognizing technology license fee revenues, net of warranty costs, if any, as the products incorporating the Neonode technology are distributed or licensed by our customers, assuming all other revenue recognition criteria has been met.  Our customers report to us the quantities of products distributed by them after the end of the reporting period stipulated in the contract, generally 30 to 45 days after the end of the month or quarter.
 
 
11

 
 
Explicit return rights are not offered to customers. There have been no returns through September 30, 2012.

Hardware Products:

We may from time-to-time develop custom hardware products for our customers that incorporate our touchscreen technology. Our policy is to recognize revenue from hardware product sales when title transfers and risk of loss has passed to the customer, which is generally upon shipment of our hardware products to our customers. We will estimate expected sales returns and record the amount as a reduction of revenue and cost of hardware and other revenue at the time of shipment. To date, we have not sold any hardware products.

                  Software Products:

We may derive revenues from software licensing sales.  We will account for the licensing of software in accordance with accounting guidance and such guidance requires judgment, including whether a software arrangement includes multiple elements, and if so, whether vendor-specific objective evidence (“VSOE”) of fair value exists for those elements.

For software license arrangements that do not require significant modification or customization of the underlying software, we will recognize new software license revenue when: (1) we enter into a legally binding arrangement with a customer for the license of software; (2) we deliver the products; (3) customer payment is deemed fixed or determinable and free of contingencies or significant uncertainties; and (4) collection is reasonably assured.

We allocate revenues to all deliverables based on their relative selling price using a specific hierarchy. The hierarchy is as follows: VSOE, third-party evidence of selling price (“TPE”) or best estimate of selling price (“BESP”).

When a sale involves multiple elements, we will allocate the entire fee from the arrangement to each respective element based on VSOE of fair value and recognize revenue when each element’s revenue recognition criteria are met. VSOE of fair value for each element is established based on the price charged when the same element is sold separately. We have established VSOE for our software licenses based on historical stand-alone sales to third parties or from the stated renewal rates contained in the customer contracts. Maintenance service revenue is recognized on a straight-line basis over the support period.

We have not yet demonstrated VSOE for the professional services that are rendered in conjunction with our software license sales. In accordance with the hierarchy we would attempt to establish the selling price of professional services using TPE. Our product contains significant differentiation such that the comparable pricing of products with similar functionality cannot be obtained. We are typically not able to obtain TPE for professional services.

When we are unable to establish selling prices using VSOE or TPE, we use BESP. The objective of BESP is to determine the price at which we would transact a sale if professional services were sold on a stand-alone basis. BESP is generally used for offerings that are not typically sold on a stand-alone basis or for highly customized offerings.

We will also continue to defer revenues that represent undelivered post-delivery engineering support until the engineering support has been completed and the software product is accepted. To date, we have not sold any software products.
 
 
12

 
 
Deferred Revenue

From time-to-time the Company receives pre-payments from its customers related to future services or future license fee revenues. The Company defers these revenues until the services have been provided or until the license fees are earned.

Advertising

Advertising costs are expensed as incurred. Advertising costs for the three and nine months ended September 30, 2012 and 2011 amounted to approximately $20,000 and $302,000, and $29,000 and $100,000, respectively.

Product Research and Development

Research and development (“R&D”) costs are expensed as incurred. R&D costs consist mainly of personnel related costs in addition to some external consultancy costs such as testing, certifying and measurements.

Stock-Based Compensation Expense
 
We measure the cost of employee services received in exchange for an award of equity instruments, including share options, based on the fair value of the award on the grant date, and recognize the value as compensation expense over the period the employee is required to provide services in exchange for the award, usually the vesting period, net of estimated forfeitures.

            We account for equity instruments issued to non-employees at their fair value and the unvested portion is re-measured each reporting period as long as the instrument requires variable accounting.

When determining stock-based compensation expense involving options and warrants, we determine the estimated fair value of options and warrants using the Black-Scholes option pricing model.

Accounting for Debt Issued with Detachable Stock Purchase Warrants and Beneficial Conversion Features

We account for debt issued with stock purchase warrants by allocating the proceeds of the debt between the debt and the detachable warrants based on the relative fair values of the debt security without the warrants and the warrants themselves, if the warrants are equity instruments.   The relative fair value of the warrants are recorded as a debt discount and amortized to expense over the life of the related debt using the effective interest method. At each balance sheet date, we make a determination if these warrant instruments should be classified as liabilities or equity, and reclassify them if the circumstances dictate.  

In certain instances, the Company enters into convertible notes that provide for an effective or actual rate of conversion that is below market value, and the embedded conversion feature does not qualify for derivative treatment (a “BCF”).  In these instances, we account for the value of the BCF as a debt discount, which is then amortized to expense over the life of the related debt using the straight-line method which approximates the effective interest method.

Income Taxes

We recognize deferred tax liabilities and assets for the expected future tax consequences of items that have been included in the consolidated financial statements or tax returns. We estimate income taxes based on rates in effect in each of the jurisdictions in which we operate. Deferred income tax assets and liabilities are determined based upon differences between the financial statement and income tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The realization of deferred tax assets is based on historical tax positions and expectations about future taxable income. Valuation allowances are recorded against net deferred tax assets when, in our opinion, realization is uncertain based on the “not more likely than not” criteria of the accounting guidance.
 
 
13

 
 
Based on the uncertainty of future pre-tax income, we fully reserved our net deferred tax assets as of September 30, 2012 and December 31, 2011. In the event we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset would increase income in the period such a determination was made. The provision for income taxes represents the net change in deferred tax amounts, plus income taxes payable for the current period.

We follow the relevant accounting guidance related to uncertain tax positions, which provisions include a two-step approach to recognizing, de-recognizing and measuring uncertain tax positions.  As a result, we did not recognize a liability for unrecognized tax benefits.  As of September 30, 2012 and December 31, 2011, we had no unrecognized tax benefits.
 
Net Loss Per Share

Net loss per share amounts have been computed based on the weighted-average number of shares of common stock outstanding during the period. Net loss per share, assuming dilution amounts from common stock equivalents, is computed based on the weighted-average number of shares of common stock and potential common stock equivalents outstanding during the period. The weighted-average number of shares of common stock and potential common stock equivalents used in computing the net loss per share for three and nine months ended September 30, 2012 and 2011 exclude the potential common stock equivalents, as the effect would be anti-dilutive (See Note 10).

Comprehensive Income (Loss)

Accounting Standards Codification (“ASC”) Topic 220, Comprehensive Income, establishes standards for reporting and displaying comprehensive income (loss) and its components in the condensed consolidated financial statements. Accumulated other comprehensive income (loss) includes foreign currency translation gains or losses as a result of consolidation.
   
Cash Flow Information

Cash flows in foreign currencies have been converted to U.S. dollars at an approximate weighted-average exchange rate for the respective reporting periods.

The weighted-average exchange rate for the consolidated statements of operations was 6.67 and 6.48 Swedish Krona to one U.S. Dollar for the three months ended September 30, 2012 and 2011, respectively. The weighted-average exchange rate for the condensed consolidated statements of operations was 6.79 and 6.41 Swedish Krona to one U.S. Dollar for the nine months ended September 30, 2012 and 2011, respectively. The exchange rate for the condensed consolidated balance sheets was 6.53 and 6.92 Swedish Krona to one U.S. Dollar as of September 30, 2012 and December 31, 2011, respectively.  

Fair Value of Financial Instruments

We disclose the estimated fair values for all financial instruments for which it is practicable to estimate fair value. Financial instruments including cash and cash equivalents, accounts receivable, payables and accrued expenses are deemed to approximate fair value due to their short maturities.
 
 
14

 
 
New Accounting Pronouncements
 
In May 2011, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Updates (“ASU”) No. 2011-4, Fair Value Measurement ("ASU 2011-04"). ASU 2011-04 amends existing guidance to achieve convergence in measurement and disclosure between U.S. GAAP and International Financial Reporting Standards ("IFRS"). ASU 2011-04 is effective for fiscal year 2012. The adoption of ASU 2011-04 did not impact the Company’s results of operations or its financial position.

In June 2011, the FASB issued ASU No. 2011-05,   Presentation of Comprehensive Income (“ASU 2011-05”).  The provisions of ASU 2011-05 allow an entity the option to present the total of comprehensive income (loss), the components of net income (loss), and the components of other comprehensive income (loss) either in a single continuous statement of comprehensive income (loss) or in two separate but consecutive statements.  In both choices, an entity is required to present each component of net income (loss) along with total net income (loss), each component of other comprehensive income (loss) along with a total for other comprehensive income (loss), and a total amount for comprehensive income (loss).  The statement(s) are required to be presented with equal prominence as the other primary financial statements.  ASU No. 2011-05 eliminates the option to present the components of other comprehensive income (loss) as part of the statement of changes in stockholders’ equity but does not change the items that must be reported in other comprehensive income (loss) or when an item of other comprehensive income (loss) must be reclassified to net income (loss).  Certain provisions of ASU No. 2011-05 are effective for the Company’s interim reporting period beginning on or after December 15, 2011, with retrospective application required.  The adoption of ASU No. 2011-05 resulted in presentation changes to the Company’s consolidated statements of operations and the addition of separate consolidated statements of comprehensive income (loss).  The adoption of ASU No. 2011-05 did not impact the Company’s results of operations or its financial position.
   
3. Convertible Debt

Senior Convertible Secured Notes- 2007

At December 31, 2011, all of convertible promissory notes (“Senior Convertible Secured Notes-2007”) have been converted in shares of our common stock. The Senior Convertible Secured Notes – 2007 were originally due August 26, 2010. On September 22, 2010, we entered into a debt modification agreement with the two holders of an aggregate of $126,362 of convertible promissory notes that were due on August 26, 2010. Based on the terms of the modification, this transaction qualified as debt extinguishment accounting under the relevant accounting guidance. As part of the debt extinguishment, the maturity date of the convertible promissory notes was extended until April 26, 2011. We entered into a debt-for-equity repayment plan whereby we were retiring the convertible promissory notes in equal installments by issuing our common stock priced at a 15% discount from the average market closing price for the five days ending on the 25th of each month over the eight month period beginning September 26, 2010 ending on April 26, 2011.  The holders of the notes had the right to convert the outstanding balance priced at $2.25 per share if the market value of our common stock is greater than $2.50 per share for five consecutive days.

During the nine months ended September 30, 2011, we issued the note holders 31,570 shares of our common stock pursuant to the debt-for-equity repayment plan and retired the remaining note principal balance on April 26, 2011. We recorded $84,657 of note principal reduction and $1,054 of interest payment.

September 2009 Senior Convertible Secured Notes Financing transaction

During the period from August 25, 2009 through December 15, 2009, we completed a private placement of convertible notes totaling $987,000 that were converted, at the holder’s option, into shares of our common stock at a conversion price of $0.50 per share (the “Convertible Notes - 2009”).  The convertible note holders had the right to have the conversion price adjusted to equal the lower stock price if we issued common stock or convertible notes at a lower conversion price than $0.50 per share during the period that the notes were outstanding. The Convertible Notes - 2009 that were originally due on December 31, 2010 were extended to June 30, 2011 (see below under Warrant Repricing and Debt Extension Financing Transaction – 2010) and bore annual interest rate of 7%, payable on June 30 and December 31 of each year that the convertible notes were outstanding. In addition, we issued 986,983 three-year warrants to the convertible note holders with an exercise price of $1.00 per share. The warrants may be exercised and converted to common stock, at the warrant holder’s option, beginning on the six-month anniversary of the date of issuance until the warrant expiration date.  As a result of the conversions and repayments during the nine months ended September 30, 2011, the Company reclassified approximately $4.6 million of the related derivative liabilities to additional paid-in capital. As of September 30, 2011, the fair value of the remaining embedded conversion features was $0 due to the repayment or conversion of all the Convertible Notes - 2009. The Company recorded a loss of $2.3 million due to the change in the fair value of the embedded conversion features of these Convertible Notes – 2009 during the nine months ended September 30, 2011. As of September 30, 2011, all of the Convertible Notes – 2009 have been paid in full with cash or have been converted to shares of our common stock.
 
 
15

 
 
The embedded conversion feature of the Convertible Notes – 2009 met the definition of a derivative financial instrument and was classified as a liability in accordance with relevant accounting guidance. The note holders had the right to convert the debt into shares of our common stock, and the notes included price protection whereby these notes were protected for as long as the notes remained outstanding against future private placements made at lower share prices, and therefore, the total number of shares of our common stock that the convertible notes can be convertible into was not fixed. The embedded conversion features were revalued on each balance sheet date and marked-to-market with the change recorded to non-cash items related to debt discounts, deferred financing fees and the valuation of conversion features and warrants on the consolidated statements of operations.

During the three and nine months ended September 30, 2011 we recorded a total of $0 and $15,000 in interest expense related to the principal balance of the Convertible Notes – 2009, respectively.

Senior Convertible Secured Notes- 2010

During the period from January through June 30, 2010, we received $1,597,000 in cash proceeds and converted $163,000 of accounts payable related to a private placement of convertible notes (the “Convertible Notes – 2010”) and stock purchase warrants that were convertible, at the holder’s option, into shares of our common stock at a conversion price of $0.50 per share and we issued 1,760,712 stock purchase warrants that had an exercise price of $1.00 per share. The convertible note holders had the right to have the conversion price adjusted to equal the lower stock price if we issued stock or convertible notes at a lower conversion price than $0.50 during the period that the notes were outstanding. These convertible notes were originally due on December 31, 2010 and were extended to June 30, 2011(see below under Warrant Repricing and Debt Extension Financing Transaction – 2010) and bore annual interest rate of 7%, payable on June 30 and December 31 of each year that the convertible notes were outstanding. The warrants may be exercised and converted to common stock, at the warrant holder’s option, beginning on the six-month anniversary date of issuance until the warrant expiration date. We are not obligated to register the common stock related to the convertible debt or the warrants. During the year ended December 31, 2011, we issued 3,557,171 shares of our common stock to holders of Convertible Notes – 2010 who converted principal of $1,750,143 and $28,442 of related accrued interest. As of December 31, 2011, all of the Convertible Notes – 2010 have been converted to shares of our common stock.

The embedded conversion feature of the convertible debt issued in the 2010 convertible debt financing transaction met the definition of a derivative financial instrument and was classified as a liability in accordance with accounting guidance. The note holders had the right to convert the debt into shares of our common stock, and the notes included price protection whereby these notes were protected for as long as the notes remain outstanding against future private placements made at lower share prices, and therefore, the total number of shares of our common stock that the convertible notes may be convertible into was not fixed. The embedded conversion features were revalued on each balance sheet date and marked to market with the increase or decrease included in fair value to non-cash items related to debt discounts and deferred financing fees and the valuation of conversion features and warrants on the condensed consolidated statements of operations. As a result of the conversions during the nine months ended September 30, 2011, the Company reclassified approximately $8.7 million of the related derivative liabilities to additional paid-in capital. As of September 30, 2011, all of the Convertible Notes – 2010 have been converted to shares of our common stock. As of September 30, 2011, the fair value of the remaining embedded conversion features is $0 as all the Convertible Notes – 2010 were converted. The Company recorded a loss of approximately $4.4 million due to the change in the fair value of the embedded conversion feature of these Convertible Notes – 2010 during the nine months ended September 30, 2011.
 
During the three and nine months ended September 30, 2011 we recorded a total of  $0 and $28,000, respectively, in interest expense related to the principal balance of the Convertible Notes – 2010.

 
16

 

Senior Convertible Secured Notes- 2011

In March 2011, we received $3.7 million in cash proceeds and commitments for an additional $491,000 related to a private placement of convertible notes, bearing interest at a rate of seven percent (7%) per annum, that matured on March 1, 2014, and that could be converted at the holder’s option into 1,691,320 shares of our common stock at a conversion price of $2.50 per share (the “Convertible Secured Notes – 2011”). The Company received the $491,000 in cash proceeds related to the unpaid commitments in April and May 2011. The notes would automatically be converted into shares of the Company’s common stock in the event that on or before the note due date either (a) the Company’s common stock is traded at a price per share of $6.25 or higher for five (5) consecutive trading days, or (b) the Company consummates a financing in the amount of at least $5 million.  In the event that the loan principal and accrued interest was not repaid by the Company by the due date, and the investor has not previously converted the note, the investor’s sole remedy for such non-payment shall be the payment of additional annual interest at a rate of 10% per year.  The accrued interest was payable in stock, using the $2.50 conversion price, or cash, at the holder’s option, on June 30 and December 31 of each year.

In addition,  as of March 31, 2011, the Company issued 373,730 new five-year common stock purchase warrants, with an exercise price of $3.13 per share (the “March 2011 Warrants”), with each investor receiving a number of March 2011 Warrants that was equal  to twenty-five percent (25%) of the investor’s note to the Company.  The Company issued an additional 49,100 warrants in April 2011 related to the collection of the payment totaling $491,000. The March 2011 Warrants may be exercised by cash payment or through cashless exercise by the surrender of warrant shares having a value equal to the exercise price of the portion of the warrants being exercised.
 
In connection with the March 2011 financing transaction the Company valued the warrants issued to the convertible note holders on a relative fair value basis using the Black-Scholes option pricing model, totaling $813,000. This relative fair value of the warrants was recorded as a debt discount. The embedded conversion features to the notes was determined to meet the definition of a derivative liability and as of the date of issuance was valued at $4.1 million. In accordance with relevant accounting guidance, the Company recorded an additional debt discount ($2.9 million) up to the full amount of the notes, recorded the derivative liability for the embedded conversion feature at $4.1 million and recorded the fair value in excess of face amount of debt as interest expense on the issuance date of $1.2 million. The debt discount was amortized in full upon the conversion of the notes to common stock on December 14, 2011. As of December 31, 2011, the fair value of the embedded conversion feature was $0 due to the conversion of all the Senior Convertible Secure Notes – 2011.
 
On June 30, 2011, the Company issued 27,851 shares of unregistered common stock to note holders of the Senior Convertible Secured Notes – 2011 private placement financing transaction in lieu of cash for their $69,628 accrued interest payment that was due June 30, 2011. In addition, the Company paid $10,277 of the accrued interest in cash to note holders who declined to convert their interest payment to stock.

As of September 30, 2011, the fair value of the embedded conversion feature was $7.6 million and as such, the Company recorded a loss on the change in fair value of the embedded conversion feature of $1.5 million and $2.8 million for the three and nine months ended September 30, 2012, respectively, which is included in the accompanying consolidated condensed statement of operations as a component on non-cash items related to debt discounts, deferred financing fees and valuation of conversion features and warrants.
 
In October and November 2011, note holders of $575,000 of the original $4.2 million Senior Convertible Secure Notes – 2011 exercised their right to convert their notes and accrued interest and were issued 232,125 shares of our common stock.
 
On December 13, 2011, following a public offering pursuant to a Registration Statement on Form S-3, the Company received gross proceeds in excess of $5 million. Pursuant to the terms, as defined, in the Senior Convertible Secure Notes – 2011 agreements, the remaining outstanding principal balance plus accrued interest, was automatically converted into shares of common stock at a conversion price of $2.50 per share. In accordance with the terms of the agreement, the Company automatically converted approximately $3.7 million of remaining principal and approximately $130,000 of accrued interest into 1,513,237 shares of the Company’s common stock. In addition, the Company issued 99,461 shares of common stock related to the bonus interest feature associated with the mandatory conversion of the debt. As of December 31, 2011, the fair value of the embedded conversion features was $0. As of December 31, 2011, all of the Senior Convertible Secure Notes - 2011 plus accrued interest was paid or converted into shares of common stock.  
 
 
17

 
 
4. Stockholders’ Equity

On February 29, 2012, the Company filed a Certificate of Correction with the Secretary of State of Delaware effectively reducing the amount of its authorized shares from 848,000,000 shares of Common Stock and 2,000,000 shares of Preferred Stock to 70,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. This reflects the new capital structure of the Company following its 1-for-25 reverse split that became effective at the close of business on March 25, 2011.

On May 1, 2012, the Company began trading its common stock on the NASDAQ Stock Market Capital Markets under trading symbol NEON.

Common Stock
 
On March 16, 2012, John Reardon, a member of our board of directors, exercised a warrant to purchase 200,000 shares of common stock using the net exercise provision allowed in the warrant and received 174,798 shares of our common stock.

During the nine months ended September 30, 2012, Series B Preferred stockholders exchanged 19 shares of Series B Preferred stock for 2,509 shares of our common stock.

 During the nine months ended September 30, 2012, warrant holders (excluding members of our board of directors) exercised warrants to purchase 116,000 shares of common stock using the net exercise provision allowed in the warrant and received 79,050 shares of our common stock. Warrant holders exercised warrants to purchase 17,500 shares of common stock and paid a cash exercise price of $3.13 per share for a total exercise price of $54,775. In addition, a warrant holder exercised a warrant to purchase 72,469 shares of common stock and paid a cash exercise price of $1.38 per share for a total exercise price of $100,007.

Preferred Stock

The terms of the Series A and Series B Preferred stock are as follows:
 
Dividends and Distributions.
 
 
Series A Preferred:
The holders of shares of Series A Preferred stock are entitled to participate with the holders of our common stock with respect to any dividends declared on the common stock in proportion to the number of shares of common stock issuable upon conversion of the shares of Series A Preferred stock held by them.
 
 
Series B Preferred:
The holders of shares of Series B Preferred stock are entitled to participate with the holders of our common stock with respect to any dividends declared on the common stock in proportion to the number of shares of common stock issuable upon conversion of the shares of Series B Preferred stock held by them.
 
 
18

 
 
Liquidation Preference.
 
 
Series A Preferred:
In the event of any liquidation, dissolution, or winding up of our operations, either voluntary or involuntary, subject to the rights of any other series of Preferred stock to be established by the Board of Directors (the “Senior Preferred Stock”), the holders of Series A Preferred stock shall be entitled to receive, after any distribution to the holders of Senior Preferred Stock and prior to and in preference to any distribution to the holders of common stock, $0.001 for each share of Series A Preferred stock then outstanding.
 
 
Series B Preferred:
In the event of any liquidation, dissolution, or winding up of our operations, either voluntary or involuntary, subject to the rights of the Series A Preferred stock and Senior Preferred Stock, the holders of Series B Preferred stock shall be entitled to receive, after any distribution to the holders of Senior Preferred Stock and prior to and in preference to any distribution to the holders of common stock, $0.001 for each share of Series B Preferred stock then outstanding.
 
Voting.
 
The holders of shares of Series A Preferred stock and Series B Preferred stock shall have one vote for each share of Series A Preferred stock and Series B Preferred stock held by them.
 
Conversion.
 
Initially, each share of Series A Preferred stock and each share of Series B Preferred stock was convertible into one share of our common stock.  Any modification to the conversion rate requires shareholder approval (see below). On March 31, 2009, our shareholders approved a resolution to increase the authorized share capital, and to increase the conversion ratio to 480.63 shares of common stock for each share of Series A Preferred stock and to 132.07 shares of our common stock for each shares of Series B Preferred stock, thus completing the restructuring begun in December 2008.  

Conversion of Preferred Stock Issued to Common Stock

On April 24, 2009, we initiated the process of allowing the shareholders of our preferred stock to convert the Series A and B Preferred stock to shares of our common stock. In order to convert the preferred stock to common stock each preferred stock shareholder is required to submit the preferred stock certificate to our transfer agent and request conversion to common stock. The conversion to common stock is not mandatory and shareholders who own preferred stock may choose not to convert their preferred stock to shares of our common stock.  The following table summarizes the Preferred stock not yet converted as of September 30, 2012.

   
Shares of Preferred Stock Not Exchanged as of September 30, 2012
   
Conversion Ratio
   
Shares of Common Stock after Conversion of all Outstanding Shares of Preferred Stock Not yet Exchanged at September 30, 2012
 
Series A Preferred stock
    83       480.63       39,892  
Series B Preferred stock
    95       132.07       12,547  
Total  Remaining Not Exchanged
    178               52,439  
 
 
19

 
 
5. Fair Value Measurement of Assets and Liabilities

Accounting guidance defines fair value, establishes a framework for measuring fair value, and expands disclosure requirements about fair value measurements. The accounting guidance does not mandate any new fair-value measurements and is applicable to assets and liabilities that are required to be recorded at fair value under other accounting pronouncements.
 
The three levels of the fair-value hierarchy are described as follows:
 
Level 1: Quoted prices (unadjusted) in active markets for identical assets and liabilities. As of September 30, 2012 and December 31, 2011, we had no level 1 assets or liabilities.
 
Level 2: Inputs other than Level 1 that are observable, either directly or indirectly. As of September 30, 2012 and December 31, 2011, we had no level 2 assets or liabilities.

Level 3: Inputs other than Level 1 that are observable, either directly or indirectly. As of September 30, 2012 and December 31, 2011, we had no level 3 assets or liabilities. 
 
   
For the Nine
   
Months Ended
September 30, 2011
     
 Annual dividend yield
 
--
 Expected life (years)
 
0.08 – 3.0
 Risk-free interest rate
 
0.08%- 1.27%
 Expected volatility
 
110% - 263%

The assumptions above were used to value warrants granted to employees and consultants as well as the embedded conversion features associated with convertible debt for the nine months ended September 30, 2011.
 
On December 14, 2011, all of the outstanding convertible debt and accrued interest was paid or converted into shares of the Company’s common stock. As of December 31, 2011, the fair value of the embedded conversion features was $0.
 
6. Deferred Revenue

Engineering development fees are recorded as deferred revenue until such time as the engineering services have been provided.

As of September 30, 2012 and December 31, 2011, we have $2.3 million and $1.5 million, respectively, of deferred license fee revenue related to a prepayment for future license fees from one customer and a total of $0.3 million and $0.4 million, respectively, of deferred engineering development fees from four customers, respectively. We are deferring the engineering development fee revenue until such time as the engineering work has been completed.
 
7. Stock-Based Compensation
 
We have three approved stock option plans for which stock options and restricted stock awards are available to grant to employees, consultants and directors. All employee and director stock options granted under our stock option plans have an exercise price equal to the market value of the underlying common stock on the grant date. There are no vesting provisions tied to performance conditions for any options, as vesting for all outstanding option grants was based only on continued service as an employee, consultant or director. All of our outstanding stock options and restricted stock awards are classified as equity instruments.

 
20

 

Stock Options

As of September 30, 2012, we had two equity incentive plans:
 
 
     
The 1998 Non-Officer Stock Option Plan (the 1998 Plan), which expired in June 2008 ;
 
      
The 2006 Equity Incentive Plan (the 2006 Plan).  

We also had one non-employee director stock option plan as of September 30, 2012:
 
 
      
The 2001 Non-Employee Director Stock Option Plan (the Director Plan), which expired in March 2011.
 
A summary of the combined activity under all of the stock option plans is set forth below:

  
 
Number of Options Outstanding
   
Weighted Average Exercise Price
 
Outstanding at January 1, 2012
   
19,324
   
$
92.19
 
Granted
   
1,505,000
     
4.29
 
Cancelled or expired
   
(8,124
   
69.36
 
Exercised
   
---
     
---
 
Outstanding at September 30, 2012
   
1,516,200
   
$
5.06
 
 
   
For the Nine
   
Months Ended
September 30, 2012
     
 Annual dividend yield
   
--
 Expected life (years)
   
3.85
 Risk-free interest rate
   
0.43% - 0.58%
 Expected volatility
   
177% - 186%

The assumptions above were used to value stock options granted to employees and directors during the nine months ended September 30, 2012.

The aggregate intrinsic value of the 1,516,200 stock options that are outstanding, vested and expected to vest at September 30, 2012 is $0.

The 1998 Plan terminated effective June 15, 2008 and the Director Plan terminated effective March 2011. Although we can no longer issue stock options out of the plans, the outstanding options at the date of termination will remain outstanding and vest in accordance with their terms. Options granted under the Director Plan vested over a one to four-year period, expire five to seven years after the date of grant and have exercise prices reflecting market value of the shares of our common stock on the date of grant. Stock options granted under the 1998 and 2006 Plans are exercisable over a maximum term of ten years from the date of grant, vest in various installments over a one to four-year period and have exercise prices reflecting the market value of the shares of common stock on the date of grant.
 
During the three and nine months ended September 30, 2011, the Company recorded $17,000 and $87,000, respectively, of stock option expense related to the vesting of stock options.
 
 
21

 
 
We did not grant any options to purchase shares of our common stock to employees or members of our Board of Directors (Board) during the nine months ended September 30, 2011.

During the three and nine months ended September 30, 2012, we granted  45,000 and 1,145,000 options to purchase shares of our common stock to employees and  0 and 360,000 options to purchase shares of our common stock to members of our Board. The options have a 7-year life and 1/3 of the options are vested on the date of grant with the remaining to vest monthly over the remaining 24-months. During the three and nine months ended September 30, 2012, we recorded approximately $572,000 and $2.9 million, respectively, of stock based compensation expense related to vesting of such options.

Warrants
 
On December 3, 2010, we issued 120,000 warrants at an exercise price of $1.625 per share to an employee. The fair value of the warrants was $198,000 on the date of grant, using the Black-Scholes option pricing model, which is to be amortized over 24 months. During the nine months ended September 30, 2012 and 2011, we recorded $25,000 and $74,000, respectively, of stock based compensation expense related to vesting of such warrants.

We issued 80,000 five-year stock purchase warrants at an exercise price of $2.50 per share to our legal advisor during the nine months ended September 30, 2011. We also issued 20,000 three-year stock purchase warrants at an exercise price of $2.00 per share in one of our US based employees during the nine months ended September 30, 2011. In addition, we issued 20,000 shares three-year stock purchase warrants at an exercise price of $4.05 per share to an engineering consultant during the nine months ended September 30, 2011. The warrants to purchase an aggregate of 120,000 shares of our common stock vested on the date of the grant. The vested warrant granted to our legal advisor has a fair value on the grant of $193,000 and is included in general and administrative expense for the nine months ended September 30, 2011. The vested warrant granted to our employee has a fair value on the date of the grant of $37,000 and is included in product research and development expense for the nine months ended September 30, 2011. The vested warrant granted to our engineering consultant has a fair value on the date of grant of $73,000 and is included in product research and development expense for the nine months ended September 30, 2011.
 
On April 25, 2011, Davisa Ltd. exercised warrants to purchase 50,000 shares of common stock. The Company recorded an additional $50,000 as stock based compensation to compensate Davisa Ltd. by waiving the $1.00 exercise price, and issued 50,000 shares of our common stock to Davisa Ltd. for services provided for the private placement of convertible notes and warrants in the March 2011 financing transaction.
 
On September 12, 2011, we issued 20,000 warrants at an exercise price of $3.90 per share to an employee. The fair value of the warrants was $75,000 on the date of grant, using the Black-Scholes option pricing model, which is to be amortized over 24 months. During the three months ended September 30, 2012 and 2011 we recorded $9,000 and $2,000, respectively, of stock based compensation expense related to vesting of such warrants. During the nine months ended September 30, 2012 and 2011 we recorded $28,000 and $2,000, respectively, of stock based compensation expense related to vesting of such warrants.

The stock-based compensation expense reflects the fair value of the vested portion of options and warrants for the recipients at the date of issuance plus the amortization of the unvested portion of the stock options and warrants. Stock-based compensation expense related to stock options and warrants in the accompanying consolidated statements of operations is as follows (in thousands):

 
22

 
 
   
Three months ended
September 30, 2011
   
Three months ended
September 30, 2012
 
Stock-based compensation
  $ 45     $ 606  

   
Nine months ended
September 30, 2011
   
Nine months ended
September 30, 2012
   
Remaining unamortized expense at
September 30, 2012
 
                Stock-based compensation
 
$
517
   
$
2,957
   
$
3,222
 

The remaining unamortized expense related to stock options and warrants will be recognized on a straight line basis monthly as compensation expense over the remaining vesting period which approximates 1.7 years.

See Note 5 for assumptions used to value warrants during the three and nine months ended September 30, 2011.

A summary of all warrant activity is set forth below:
 
   
September 30, 2012
 
Outstanding and exercisable
 
Warrants
   
Weighted Average Exercise Price
   
Weighted Average Remaining Contractual Life
 
January 1, 2012
   
5,405,606
   
$
0.57
     
3.56
 
   Issued
   
--
   
$
--
     
--
 
   Expired/forfeited
   
(62,384
   
1.25
     
--
 
   Exercised
   
(343,817
)
 
$
1.03
     
--
 
Outstanding and exercisable, September 30, 2012
   
4,999,405
   
$
1.60
     
1.63
 

On March 16, 2012, John Reardon, a member of our board of directors, exercised a warrant to purchase 200,000 shares of common stock using the net exercise provision allowed in the warrant and received 174,798 shares of our common stock.

During the nine months ended September 30, 2012, warrant holders (excluding members of our board of directors) exercised warrants to purchase 116,000 shares of common stock using the net exercise provision allowed in the warrant and received 79,050 shares of our common stock. Warrant holders exercised warrants to purchase 17,500 shares of common stock and paid a cash exercise price of $3.13 per share for a total exercise price of $54,775. In addition, a warrant holder exercised a warrant to purchase 72,469 shares of common stock and paid a cash exercise price of $1.38 per share for a total exercise price of $100,007.

 
23

 

The fair value of stock-based awards to employees and directors is calculated using the Black-Scholes option pricing model, even though this model was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which differ significantly from our stock options. The Black-Scholes model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. The expected term and forfeiture rate of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior, as well as expected behavior on outstanding options. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. The expected volatility is based on the historical volatility of our stock price. These factors could change in the future, which would affect fair values of stock options granted in such future periods, and could cause volatility in the total amount of the stock-based compensation expense reported in future periods.

Below is a summary of Outstanding Warrants to Purchase
Common Stock as of September 30, 2012:
 
 
Description
 
Issue Date
   
Exercise Price
   
Shares
   
Expiration Date
 
                                 
August 2009 Employee Warrants
 
8/25/2009
    $ 0.50       240,000    
8/25/2016
 
January 2010 Investor Warrant
 
1/28/2010
    $ 1.00       40,000    
1/28/2013
 
2007 Debt Extension Warrants
 
9/22/2010
    $ 1.00       16,000    
9/22/2015
 
September 2010 Repricing Warrant
 
9/28/2010
    $ 1.38       4,000    
9/28/2013
 
October 2010 Repricing Warrants
 
10/18/2010
    $ 1.38       2,312,362    
10/18/2013
 
October 2010 Employee Warrants
 
10/15/2010
    $ 1.38       1,400,000    
10/15/2013
 
December 2010 Employee Warrants
 
12/3/2010
    $ 1.63       200,000    
12/3/2015
 
January 2011 Employee Warrant
 
1/21/2011
    $ 2.00       20,000    
1/21/2014
 
February 2011 Legal Advisor Warrant
 
2/22/2011
    $ 2.00       80,000    
2/22/2016
 
March  2011 Investor Warrants
 
3/9/2011
    $ 3.13       612,943    
3/9/2016
 
March  2011 Investor Warrants
 
4/7/2011
    $ 3.13       34,100    
4/7/2016
 
May 2011 Consultant Warrant
 
5/17/2011
    $ 4.05       20,000    
5/17/2014
 
September 2011 Employee Warrant
 
9/12/2011
    $ 3.90       20,000    
9/12/2014
 
Total Warrants Outstanding
                    4,999,405          

8. Commitments and Contingencies

Indemnities and Guarantees

We have agreed to indemnify each of our executive officers and directors for certain events or occurrences arising as a result of the officer or director serving in such capacity. The term of the indemnification period is for the officer's or director's lifetime. The maximum potential amount of future payments we could be required to make under these indemnification agreements is unlimited.  However, we have directors’ and officers’ liability insurance policy that should enable us to recover a portion of future amounts paid. As a result of our insurance policy coverage, we believe the estimated fair value of these indemnification agreements is minimal and have no liabilities recorded for these agreements as of September 30, 2012 and December 31, 2011, respectively.

           We enter into indemnification provisions under our agreements with other companies in the ordinary course of business, typically with business partners, contractors, customers and landlords. Under these provisions we generally indemnify and hold harmless the indemnified party for losses suffered or incurred by the indemnified party as a result of our activities or, in some cases, as a result of the indemnified party's activities under the agreement. These indemnification provisions often include indemnifications relating to representations made by us with regard to intellectual property rights. These indemnification provisions generally survive termination of the underlying agreement. The maximum potential amount of future payments we could be required to make under these indemnification provisions is unlimited. We have not incurred material costs to defend lawsuits or settle claims related to these indemnification agreements. As a result, we believe the estimated fair value of these agreements is minimal. Accordingly, we have no liabilities recorded for these agreements as of September 30, 2012 and December 31, 2011, respectively.

 
24

 
 
            Operating Leases

On March 22, 2012, we entered into a three year lease with 2350 Mission Investors LLC for 3,185 square feet of office space located at 2350 Mission College Blvd, Suite 190, Santa Clara, CA 95054 USA commencing May 1, 2012. The initial lease payment is approximately $7,000 per month, increasing to approximately $7,700 per month over the term of the lease. The annual payment for this space equates to approximately $84,000 per year including property taxes.

 On April 15, 2012, Neonode Technologies AB entered into a lease with No Picnic for 2,853 square feet of office space located at Storgatan 23C, Stockholm, Sweden for approximately $13,000 per month including property tax (excluding VAT). The annual payment for this space equates to approximately $161,000 per year including property tax (excluding VAT). This lease is valid through April 15, 2013.

Neonode Technologies AB has a lease with Vasakronan Fastigheter AB for 2,723 square feet of office space located at Linnegatan 89D, Stockholm, Sweden for approximately $8,000 per month including property tax (excluding VAT). The annual payment for this space equates to approximately $93,000 per year including property tax (excluding VAT). This lease is valid through December 31, 2014, with a 9-month notice period. The contract will be extended for an additional 3 years if it is not terminated according to the terms in the contract.

9.  Segment Information

The Company has one reportable segment, which is comprised of the touchscreen technology licensing business. All of our sales for the three and nine months ended September 30, 2012 and 2011 were to customers located in the U.S., Europe and Asia.

The following table presents net revenues by geographic region for the three and nine months ended September 30, 2012 and 2011 (dollars in thousands):

   
Three months ended
September 30, 2012
   
Three months ended
September 30, 2011
 
   
Amount
   
Percentage
   
Amount
   
Percentage
 
Net revenues made in the U.S.
 
$
877
     
52
%
 
$
741
     
58
%
                                 
Net revenues made outside of the U.S.
   
802
     
48
%
   
546
     
42
%
                                 
   
$
1,679
     
100
%
 
$
1,287
     
100
%
 
   
Nine months ended
September 30, 2012
   
Nine months ended
September 30,
2011
 
   
Amount
   
Percentage
   
Amount
   
Percentage
 
Net revenues made in the U.S.
 
$
2,809
     
58
%
 
$
955
     
45
%
                                 
Net revenues made outside of the U.S.
   
2,008
     
42
%
   
1,154
     
55
%
                                 
   
$
4,817
     
100
%
 
$
2,109
     
100
%

10. Net Loss Per Share

Basic net loss per common share for the three and nine months ended September 30, 2012 and 2011 was computed by dividing the net loss for the relevant period by the weighted average number of shares of common stock outstanding. Diluted earnings per common share is computed by dividing net loss attributable to common stockholders by the weighted average number of shares of common stock and common stock equivalents outstanding.
 
 
25

 
 
Potential common stock equivalents of 103,000 and 19,324 stock options outstanding under the treasury stock method, 3.2 million and 5.4 million outstanding stock warrants under the treasury stock method, 52,000 and 55,000 shares issuable upon conversion of preferred stock and zero and 1.7 million shares issuable upon conversion of notes are excluded from the diluted earnings per share calculation for the nine months ended September 30, 2012 and 2011, respectively, due to their anti-dilutive effect. 

   
Three Months ended
 
(in thousands, except per share amounts)
 
September 30,
 
   
2012
   
2011
 
BASIC AND DILUTED
           
Weighted average number of
           
common shares outstanding
   
33,021
     
27,934
 
Number of shares for computation of
               
net loss per share
   
33,021
     
27,934
 
Net loss
 
$
(2,144
)
 
$
(1,930
)
                 
Net loss per share - basic and diluted
 
$
(0.06
)
 
$
(0.07
)

   
Nine Months ended
 
(in thousands, except per share amounts)
 
September 30,
 
   
2012
   
2011
 
BASIC AND DILUTED
           
Weighted average number of
           
common shares outstanding
   
32,934
     
26,050
 
Number of shares for computation of
               
net loss per share
   
32,934
     
26,050
 
Net loss
 
$
(7,159
)
 
$
(14,373
)
                 
Net loss per share - basic and diluted
 
$
(0.22
)
 
$
(0.55
)
 
11. Subsequent Events

We have evaluated subsequent events through the filing date of this Form 10-Q, and have determined that no subsequent events have occurred that would require recognition in the consolidated financial statements or disclosure in the notes thereto.
 
 
26

 

Item 2.    Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward Looking Statements

This Quarterly Report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, adopted pursuant to the Private Securities Litigation Reform Act of 1995.  Statements that are not purely historical may be forward-looking.  You can identify some forward-looking statements by the use of words such as "believes," "anticipates," "expects," "intends" and similar expressions.  Forward- looking statements involve inherent risks and uncertainties regarding events, conditions and financial trends that may affect our future plans of operation, business strategy, results of operations and financial position.  A number of important factors could cause actual results to differ materially from those included within or contemplated by such forward-looking statements, including, but not limited to risks relating to the uncertainty of growth in market acceptance for our technology, a history of losses since inception, our ability to remain competitive in response to new technologies, the costs to defend, as well as risks of losing, patents and intellectual property rights, a reliance on our future customers’ ability to develop and sell products that incorporate our technology, the concentration of our operations in a limited number of facilities, the uncertainty of demand for our technology in certain markets, our ability to manage growth effectively, our dependence on key members of our management and development team, our limited experience in conducting operations internationally, and our ability to obtain adequate capital to fund future operations, For a discussion of these and other factors that could cause actual results to differ from those contemplated in the forward-looking statements, please see the discussion under ‘‘Risk Factors’’ contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in our publicly available filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only as of the date hereof.  Actual events or results may differ materially from the results discussed in or implied by the forward-looking statements. We do not undertake any responsibility to update or revise any of these factors or to announce publicly any revisions to forward-looking statements, whether as a result of new information, future events or otherwise.

The following management’s discussion and analysis of the Company’s financial condition and results of the operations should be read in conjunction with the condensed consolidated financial statements and the notes thereto included in Item 1 of this Quarterly Report on Form 10-Q and consolidated financial statements and notes thereto as of December 31, 2011 and 2010 and for the years then ended included in our Annual Report on Form 10-K for the year ended December 31, 2011.
   
Overview
 
Neonode Inc., “we”, “us”, “our”, the “Company”, develops and licenses MultiSensing TM touch user interfaces and optical multi-touch solutions. The cornerstone of our interface solutions is zForce®, our patented touch technology. Based on zForce, Neonode has developed a variety of features that sense any object - its size, its pressure on a surface, its depth, its velocity and even its proximity to any type of surface. This feature set is branded MultiSensing™ touch technology. Neonode MultiSensing touch technology is suited for consumer and industrial electronic devices and supports unlimited gestures, multi-touch and sweep navigation.

 Neonode licenses the MultiSensing TM touch technology to Original Equipment Manufacturers (“OEMs”) and Original Design Manufacturers (“ODMs”) who embed our technology into devices that they produce and sell. Neonode’s MultiSensing technology, rivaling the best capacitive solutions at a fraction of the cost, is being incorporated into wide array of high volume color LCD products worldwide: mobile phones, tablets, office equipment, in-car infotainment displays, GPS, gaming devices and toys. Many of these products are predicted to ramp within 6-9 months and will incorporate Neonode’s customized Texas Instrument’s (“TI”) NN1001 multi-sensing controller chip, developed in close collaboration with Texas Instruments. The TI NN1001 controller chip began shipping to customers in May 2012. To date the Neonode’s MultiSensing solution is used on more than 10 million touch consumer devices in the global market place.

Our technology licensing model allows us to focus on the development of solutions for multi-touch enabled screens, and thus we do not have to manufacture products. We license the right to use zForce and Neonode MultiSensingTM software which, together with standard components from partners, create a complete optical touch solution.
 
 
27

 
 
Intellectual Property
 
We rely on a combination of intellectual property laws, as well as confidentiality procedures and contractual provisions, to protect our proprietary technology and our brand. We have registered, and applied for the registration of, U.S. and international trademarks, service marks, domain names, and copyrights. Additionally, we have filed U.S. and international patent applications covering certain of our proprietary technology. Over time, we have assembled a portfolio of patents, trademarks, service marks, copyrights, domain names, and trade secrets covering our products and services. Our proprietary technology is not dependent on any single patent or copyright or groups of related patents or copyrights. We believe the duration of our patents is adequate relative to the expected lives of our products. Although we rigorously protect our proprietary technology, any significant impairment of, or third-party claim against, our intellectual property rights could harm our business or our ability to compete.

Critical Accounting Policies

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America. The condensed consolidated financial statements for the three and nine months ended September 30, 2012 and 2011, and as of September 30, 2012 and December 31, 2011 include the accounts of Neonode Inc. and our wholly owned subsidiary, Neonode Technologies AB.  All inter-company accounts and transactions have been eliminated in consolidation. As we have not made any changes to our critical accounting policies for the nine months ended September 30, 2012, please note the critical accounting policies disclosed in our annual report on Form 10-K for the year ended December 31, 2011.
 
Results of Operations

Net Revenues

Net revenues for the three and nine months ended September 30, 2012 was $1.7 million and $4.8 million compared to net revenue for the three and nine months ended September 30, 2011 of $1.3 million and $2.1 million, respectively.  Our net revenues for the three and nine months ended September 30, 2012 included $1.6 million and $4.1 million from license fees  plus $120,000 and $765,000 in fees for engineering design services related to our touch screen solution for customers.  Our net revenues for the three and nine months ended September 30, 2011 included $1.2 million and $1.8 million, respectively, from license fees related to the shipment of e-Readers. Net revenues for the three and nine months ended September 30, 2011 also included $82,000 and $299,000, respectively, in fees for engineering design services related to our touch screen solution for numerous customers.

As of September 30, 2012, we have twenty signed technology license agreements with global OEMs and customers. We signed two new license agreements with a global OEM subsequent to September 30, 2012. We currently have technology license agreements with OEMs who operate in the e-Reader, tablet, automotive, personal computer, printer and office equipment, toys and gaming, GPS and mobile phone markets.  In addition, we are currently developing prototype products and are engaged in product engineering design discussions with numerous global OEMs who are in the process of qualifying our touchscreen technology for incorporation in various products such as printer products, GPS devices, e-Readers, tablets, touch panels for automobiles, household appliances, mobile phones and games and toys. The development and product release cycle for these products typically takes six to eighteen months.

Drivers of the touch screen market include mobile phones, printers, laptops, tablets, e-Readers, navigation screens, etc.   The proliferation and mass market acceptance of touch screens have prompted new applications and uses for existing and new offerings, thus making the production and utilization of these modules one of the fastest growing tech segments. The typical sales cycle is 9-18 months with new customers while existing customer lead times are typically 6-9 months. During the initial cycle, there are three phases: evaluation, design, and commercial.  In the evaluation phase, prospects validate the Neonode technology using a Neonode evaluation kit and may produce short runs. During the design phase, true product development begins, with solution definition occurring as well.  This phase tends to be the longest and it should be noted that this phase is where delays typically occur, drawing out the term of the overall cycle.  In the final phase, commercialization, the customer enters into full production mode, and Neonode earns license revenue.

 
28

 
 
Gross Margin

Gross margin was $1.3 million and $3.7 million for the three and nine months ended September 30, 2012 compared to $1.0 million and $1.4 million for the same periods in 2011, respectively. Our cost of revenues includes the direct cost of production of the components, costs of Company employed engineering personnel and engineering consultants to complete the engineering design contract. The gross margin related to our license fees is 100% and as license fees as a percentage of our total revenues increase our gross margin will increase.

Product Research and Development

Product research and development (R&D) expenses for the three and nine months ending September 30, 2012 were $1.5 million and $3.6 million compared to $0.4 million and $1.0 million for the same periods in 2011.  R&D costs mainly consist of personnel related costs in addition to some external consultancy costs such as testing, certifying and measurements.   Factors that contributed to the increase in R&D costs include an increase in the amount of time our engineering department spends engaged in R&D activities. Included in R&D expenses are $73,000 and $260,000 of non-cash stock option and warrant expense for the three and nine months ended September 30, 2012 compared to $2,000 and $111,000 for the same periods in 2011. Other costs related to customer specific activities are included in our cost of revenue.

Sales and Marketing

Sales and marketing (S&M) expenses for the three and nine months ending September 30, 2012 were $0.9 million and $3.4 million compared to $0.4 million and $1.1 million for the same periods in 2011, respectively. This increase in 2012 as compared to 2011 is primarily related to an increase in sales and marketing staff, marketing activities and travel related costs. Marketing related expense were $100,000 and $302,000 for the three and nine months ended September 30, 2012 compared to $26,000 and $29,000 for the same periods in 2011. Included in S&M expenses are $250,000 and $1.2 million of non-cash stock option and warrant expense for the three and nine months ended September 30, 2012 compared to $23,000 and $70,000 for the same periods in 2011.

General and Administrative

General and administrative (G&A) expenses for the three and nine months ending September 30, 2012 were $1.1 million and $3.8 million compared to $0.5 million and $2.3 million for the same periods in 2011, respectively. This increase in 2012 as compared to 2011 is primarily related to salary expense, stock based compensation expense, legal expenses related to patent filings, corporate and SEC compliance and customer contracts. Included in G&A expenses are $284,000 and $1.5 million of non-cash stock option and warrant expense for the three and nine months ended September 30, 2012 compared to $17,000 and $336,000 for the same periods in 2011.
 
Interest Expense

Interest expense for the three and nine months ending September 30, 2011 was $76,000 and $211,000, respectively. We did not have any interest expense for the three and nine months ending September 30, 2012. We had $3.9 million of convertible debt outstanding at September 30, 2011. All the convertible debt and accrued interest was converted to shares of our common stock or paid by December 14, 2011.

Non-cash items related to debt discounts, deferred financing fees and the valuation of conversion features and warrants

In connection with the March and April 2011 financing transactions the Company determined that the embedded conversion feature to the notes meet the definition of a derivative liability, and as of the date of issuance was valued at $4.8 million. In accordance with relevant accounting guidance, the Company recorded a full debt discount up to the face amount of the notes ($4.2 million), recorded the derivative liability for the embedded conversion feature of $4.8 million and recorded the excess value of $1.5 million on the issuance as non-cash interest expense.

During the three and nine months ended September 30, 2011, the Company recorded an aggregate loss of $1.5 million and $9.6 million, respectively, as a change in fair value of derivative liabilities.
 
 
29

 
 
On December 14, 2011, all of the outstanding convertible debt and accrued interest was paid or converted into shares of the Company’s common stock. As of December 31, 2011, the fair value of the embedded conversion features was $0.

Income Taxes

Our tax provision for the three and nine months ending September 30, 2012 and 2011 represents income taxes withheld by one of our foreign customers. We recorded valuation allowances for the three and nine months ending September 30, 2012 and 2011 for deferred tax assets related to net operating losses due to the uncertainty of realization. In the event of future taxable income, our effective income tax rate in future periods could be lower than the statutory rate as such tax assets are realized.

Net Loss

As a result of the factors discussed above, we recorded a net loss of $2.1 million and $7.2 million for the three and nine months ended September 30, 2012, compared to a net loss of $1.9 million and $14.4 million in the comparable periods in 2011.
 
Off-Balance Sheet Arrangements

We do not have any transactions, arrangements, or other relationships with unconsolidated entities that are reasonably likely to affect our liquidity or capital resources other than the operating leases noted in Note 8 of the accompanying condensed consolidated financial statements. We have no special purpose or limited purpose entities that provide off-balance sheet financing, liquidity, or market or credit risk support; or engage in leasing, hedging, research and development services, or other relationships that expose us to liability that is not reflected on the face of the condensed consolidated financial statements.

Liquidity and Capital Resources

Our liquidity is dependent on many factors, including sales volume, operating profit and the efficiency of asset use and turnover. Our future liquidity will be affected by, among other things:

●  
actual versus anticipated licensing of our technology;
●  
our actual versus anticipated operating expenses;
●  
the timing of our OEM customer product shipments;
●  
the timing of payment for our technology licensing agreements;
●  
our actual versus anticipated gross profit margin;
●  
our ability to raise additional capital, if necessary; and
●  
our ability to secure credit facilities, if necessary.

Our cash is subject to interest rate risk. We invest primarily on a short-term basis. Our financial instrument holdings at September 30, 2012, were analyzed to determine their sensitivity to interest rate changes. The fair values of these instruments were determined by net present values. In our sensitivity analysis, the same change in interest rate was used for all maturities and all other factors were held constant. If interest rates increased by 10%, the expected effect on net loss related to our financial instruments would be immaterial. The functional currency of our foreign subsidiary is the applicable local currency, the Swedish Krona, and is subject to foreign currency exchange rate risk. Any increase or decrease in the exchange rate of the U.S. Dollar compared to the Swedish Krona will impact Neonode’ future operating results.
 
 
30

 
 
At September 30, 2012, we had cash of $11.2 million as compared to $12.9 million at December 31, 2011. In the nine month period ended September 30, 2012, $1.6 million of cash was used in operating activities. Our net loss for the nine months ended September 30, 2012 increased by the following non-cash items (in thousands):

Depreciation and amortization
 
$
68
 
Stock-based compensation expense
   
2,957
 
 Total net non-cash items included in cash provided by our operations
 
$
3,025
 

Working capital was $9.3 million (current assets less current liabilities) at September 30, 2012, compared to working capital of $13.6 million at December 31, 2011.

For the nine months ended September 30, 2012, we used $1.6 million of cash for operations primarily as a result of the net loss of $7.2 million including non-cash expenses of $3.0 million (as described above). Offsetting the cash impact of our net operating loss (excluding non-cash items) was a decrease in accounts receivable of $1.8 million. Such decrease was offset by the increases in accounts payable and accrued expenses of $0.1 million, deferred revenue of $0.7 million and prepaid expenses of $0.1 million.

Net cash used in investing activities totaled $0.3 million during the nine months ended September 30, 2012, and was primarily attributable to the purchase of computers and furniture related to one of our Stockholm offices.
 
Net cash provided by financing activities totaled $0.2 million during the nine months ended September 30, 2012, and resulted from the exercise of warrants for shares of our common stock.

Historically, the majority of our cash has been provided by borrowings from senior secured notes and bridge notes that have been convertible into shares of our common stock or from the sale of our common stock and common stock purchase warrants to private investors. During 2011, we raised approximately $15.5 million through debt and equity offerings.  We believe we have sufficient cash to operate for at least the next twelve months.
 
In the future, we may require sources of capital in addition to cash on hand to continue operations and to implement our strategy. If our operations do not become cash flow positive, we may be forced to seek credit line facilities from financial institutions, additional private equity investment or debt arrangements. No assurances can be given that we will be successful in obtaining such additional financing on reasonable terms, or at all. If adequate funds are not available on acceptable terms, or at all, we may be unable to adequately fund our business plans and it could have a negative effect on our business, results of operations and financial condition. In addition, if funds are available, the issuance of equity securities or securities convertible into equity could dilute the value of shares of our common stock and cause the market price to fall, and the issuance of debt securities could impose restrictive covenants that could impair our ability to engage in certain business transactions.

Item 3.   Quantitative and Qualitative Disclosures about Market Risk

Not Applicable

Item 4.   Controls and Procedures

Disclosure Controls and Procedures

Under the supervision of and with the participation of our management, including the Company’s Chief Executive Officer and Chief Financial Officer, we evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report. Based upon that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective.
 
During the three months ended September 30, 2012, management determined that we had material weaknesses relating to the segregation of duties within our accounting functions and our quarterly and annual financial close processes. A material weakness is a deficiency, or a combination of deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of a Company’s annual or interim financial statements will not be prevented or detected on a timely basis. Because these material weaknesses as to internal control over financial reporting also bear upon our disclosure controls and procedures, our Chief Executive Officer and Chief Financial Officer were unable to conclude that our disclosure controls and procedures were effective.
 
 
31

 
 
Despite the conclusion that disclosure controls and procedures were not effective as of the end of the period covered by this report, the Chief Executive Officer and Chief Financial Officer believe that the consolidated financial statements and other information contained in this quarterly report present fairly, in all material respects, our business, financial condition and results of operations.

Internal Control over Financial Reporting

There were no changes in our internal controls over financial reporting during the period covered by this report that have materially affected or are reasonably likely to materially affect our internal controls over financial reporting.

We are currently taking steps to both remedy the material weaknesses described above and facilitate our management’s assessment of internal control over financial reporting in accordance with the Sarbanes-Oxley Act and Commission rules. Our remediation steps include:

 
We added personnel to our accounting department, consultants, or other resources (including those with public company reporting experience) to enhance our policies and procedures, including those related to complex accounting issues;
 
 
We retained a Sarbanes-Oxley consulting firm to assist us to prepare written policies and procedures for accounting and financial reporting to establish a formal process to close our books and account for all transactions.
 
PART II.   Other Information

ITEM  1.    Legal Proceedings

We are not currently involved in any material legal proceedings. However, from time to time, we may become subject to additional legal proceedings, claims, and litigation arising in the ordinary course of business, including, but not limited to, employee, customer and vendor disputes
 
ITEM  1A.  Risk Factors

Please refer to Risk Factors in our Annual Report on Form 10-K for the year ended December 31, 2011.

ITEM 6.     Exhibits

Exhibits
 
Exhibit #
 
  Description
3.1
 
Amended and Restated Certificate of Incorporation of Neonode Inc., dated April 17, 2009 (incorporated by reference to Exhibit 10.22 of our Quarterly Report on Form 10-Q filed on August 4, 2009).
3.1.1
 
Certificate of Amendment, dated December 13, 2010 (incorporated by reference to Exhibit 3.1.1 of our Annual Report on Form 10-K filed on March 31, 2011)
3.1.2
 
Certificate of Amendment, dated March 18, 2011 (incorporated by reference to Exhibit 3.1 of our Current Report on Form 8-K filed on March 28, 2011)
3.1.3
 
Certificate of Correction, dated February 29, 2012 (incorporated by reference to Exhibit 3.1.3 of our Annual Report on Form 10-K filed on March 31, 2012)
3.2
Bylaws, as amended through December 5, 2007 (incorporated by reference to Exhibit 3.2 of our Annual Report on Form 10-K filed on April 15, 2008)
31.1
Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002
31.2
Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act Of 2002
32.1
Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101
The following materials from the Company’s Form 10-Q for the quarter ended September 30, 2012 and 2011, formatted in XBRL (eXtensible Business Reporting Language): (i) Consolidated Balance Sheets; (ii) Consolidated Statements of Operations; (iii) Consolidated statements of Comprehensive Loss; (iv) Consolidated Statements of Cash Flows; and (v) Notes to Consolidated Financial Statements*
 
* Pursuant to Rule 406T of Regulation S-T, the Interactive Data Files on Exhibit 101 hereto are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, and otherwise are not subject to liability under those sections

 
32

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly this report to be signed on its behalf by the undersigned thereunto duly authorized, on November 14, 2012.

 
Neonode Inc.
Registrant
 
       
Date:  November 14, 2012  
By:
/s/ David W. Brunton
 
   
David W. Brunton
 
   
Chief Financial Officer,
 
   
Vice President, Finance
 
   
and Secretary
 
   
(Principal Financial and
 
   
Accounting Officer)
 
 
 
33

EX-31.1 2 f10q0912ex31i_neonode.htm CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 f10q0912ex31i_neonode.htm
EXHIBIT 31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, Thomas Eriksson, certify that:

1.           I have reviewed this quarterly report on Form 10-Q of Neonode Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

  a)           Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under the supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report  based on such evaluation; and
 
  d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.           The registrant’s other certifying officers(s) and I have disclosed, based on our most recent evaluation of internal controls over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

  a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
  b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
 
/s/ Thomas Eriksson
     
Thomas Eriksson 
     
Chief Executive Officer
     
November14, 2012  
     
 
EX-31.2 3 f10q0912ex31ii_neonode.htm CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 f10q0912ex31ii_neonode.htm
EXHIBIT 31.2

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

I, David W. Brunton certify that:

1.           I have reviewed this quarterly report on Form 10-Q of Neonode Inc.;

2.           Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.           Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.           The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13(a)-15(e) and 15(d)-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d -15(f)) for the registrant and we have:

  a)           Designed such disclosure controls and procedures or caused such disclosure controls and procedures to be designed under the supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 
  b)           Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 
  c)           Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report  based on such evaluation; and
 
  d)           Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during registrant’s most recent fiscal quarter (the registrant’s fourth quarter in the case of an annual report) that has materially affected or is reasonably likely to materially affect, the registrant’s internal control over financial reporting: and

5.           The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal controls over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors (or persons performing the equivalent function):

  a)           All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
 
  b)           Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

/s/ David W. Brunton
 
David W. Brunton
 
Chief Financial Officer
 
Vice President, Finance
 
and Secretary
 
November 14, 2012
 
 
EX-32.1 4 f10q0912ex32i_neonode.htm CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 f10q0912ex32i_neonode.htm
EXHIBIT 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

Pursuant to the requirement set forth in Rule 13a-14(b) under the Securities Act of 1934, as amended (the “Exchange Act”) and Section 1350 of Title 18 of the United States Code, the undersigned officers of Neonode Inc. (the “Company”) each hereby certifies that, to his knowledge:

1.  
The Quarterly Report on Form 10-Q for the quarter ended September 30, 2012 filed with the Securities and Exchange Commission (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and
2.  
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
 
/s/ Thomas Eriksson
   
/s/ David W. Brunton
 
Thomas Eriksson 
   
David W. Brunton
 
Chief Executive Officer
   
Chief Financial Officer
 
November 14, 2012  
   
Vice President, Finance
 
     
and Secretary
 
     
November 14, 2012
 
EX-101.INS 5 neond-20120930.xml 0000087050 neond:SeptemberTwoThousandNineSeniorConvertibleSecuredNotesFinancingTransactionMember 2009-12-15 0000087050 neond:SeptemberTwoThousandNineSeniorConvertibleSecuredNotesFinancingTransactionMember 2009-08-25 2009-12-15 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2010-01-01 2010-06-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2010-06-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandSevenMember 2010-09-22 0000087050 us-gaap:WarrantMember 2010-12-03 0000087050 2010-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2010-12-31 0000087050 2010-12-01 2010-12-31 0000087050 us-gaap:WarrantMember 2010-12-01 2010-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-01-01 2011-03-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-03-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-03-01 2011-03-31 0000087050 2011-04-25 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-04-30 0000087050 2011-04-01 2011-04-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-04-01 2011-04-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2011-01-01 2011-06-30 0000087050 2011-06-30 0000087050 neond:SeptemberTwoThousandNineSeniorConvertibleSecuredNotesFinancingTransactionMember 2011-06-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-06-30 0000087050 2011-09-12 0000087050 us-gaap:WarrantMember 2011-09-12 0000087050 2011-07-01 2011-09-30 0000087050 neond:SeptemberTwoThousandNineSeniorConvertibleSecuredNotesFinancingTransactionMember 2011-07-01 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2011-07-01 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-07-01 2011-09-30 0000087050 country:US 2011-07-01 2011-09-30 0000087050 neond:OutsideOfUnitedStatesMember 2011-07-01 2011-09-30 0000087050 us-gaap:StockOptionsMember 2011-07-01 2011-09-30 0000087050 neond:FiveYearStockPurchaseWarrantsMember 2011-07-01 2011-09-30 0000087050 neond:StockOptionsAndWarrantsMember 2011-07-01 2011-09-30 0000087050 neond:WarrantsOneMember 2011-07-01 2011-09-30 0000087050 2011-01-01 2011-09-30 0000087050 neond:SeptemberTwoThousandNineSeniorConvertibleSecuredNotesFinancingTransactionMember 2011-01-01 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2011-01-01 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandSevenMember 2011-01-01 2011-09-30 0000087050 us-gaap:WarrantMember 2011-01-01 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-01-01 2011-09-30 0000087050 country:US 2011-01-01 2011-09-30 0000087050 neond:OutsideOfUnitedStatesMember 2011-01-01 2011-09-30 0000087050 us-gaap:StockOptionsMember 2011-01-01 2011-09-30 0000087050 neond:FiveYearStockPurchaseWarrantsMember 2011-01-01 2011-09-30 0000087050 neond:StockOptionsAndWarrantsMember 2011-01-01 2011-09-30 0000087050 neond:ThreeYearStockPurchaseWarrantsMember 2011-01-01 2011-09-30 0000087050 us-gaap:WarrantMember 2011-01-01 2011-09-30 0000087050 us-gaap:ConvertiblePreferredStockMember 2011-01-01 2011-09-30 0000087050 us-gaap:ConvertibleDebtSecuritiesMember 2011-01-01 2011-09-30 0000087050 neond:WarrantsOneMember 2011-01-01 2011-09-30 0000087050 2011-09-30 0000087050 neond:SeptemberTwoThousandNineSeniorConvertibleSecuredNotesFinancingTransactionMember 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2011-09-30 0000087050 us-gaap:WarrantMember 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-09-30 0000087050 neond:FiveYearStockPurchaseWarrantsMember 2011-09-30 0000087050 neond:ThreeYearStockPurchaseWarrantsMember 2011-09-30 0000087050 2010-06-01 2011-09-30 0000087050 us-gaap:WarrantMember 2011-09-01 2011-09-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-10-01 2011-11-30 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-12-13 0000087050 2011-12-31 0000087050 neond:SeptemberTwoThousandNineSeniorConvertibleSecuredNotesFinancingTransactionMember 2011-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2011-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandSevenMember 2011-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-12-31 0000087050 us-gaap:SeriesAPreferredStockMember 2011-12-31 0000087050 us-gaap:SeriesBPreferredStockMember 2011-12-31 0000087050 neond:FutureLicenseFeesFromOneCustomerMember 2011-12-31 0000087050 neond:DeferredEngineeringDevelopmentFeesFromFourMember 2011-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandTenMember 2011-12-01 2011-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandSevenMember 2011-12-01 2011-12-31 0000087050 neond:SeniorConvertibleSecuredNotesTwoThousandElevenMember 2011-12-01 2011-12-31 0000087050 2012-02-29 0000087050 2012-02-01 2012-02-29 0000087050 2012-03-16 0000087050 us-gaap:CommonStockMember 2012-03-16 0000087050 neond:MissionInvestorsLlcMember 2012-03-22 0000087050 neond:MissionInvestorsLlcMember 2012-03-01 2012-03-31 0000087050 neond:MissionInvestorsLlcMember neond:MonthMember 2012-03-01 2012-03-31 0000087050 neond:MissionInvestorsLlcMember neond:AnnualMember 2012-03-01 2012-03-31 0000087050 neond:PicnicMember 2012-04-15 0000087050 neond:PicnicMember 2012-04-01 2012-04-30 0000087050 neond:PicnicMember neond:MonthMember 2012-04-01 2012-04-30 0000087050 neond:PicnicMember neond:AnnualMember 2012-04-01 2012-04-30 0000087050 2012-07-01 2012-09-30 0000087050 country:US 2012-07-01 2012-09-30 0000087050 neond:OutsideOfUnitedStatesMember 2012-07-01 2012-09-30 0000087050 us-gaap:StockOptionsMember 2012-07-01 2012-09-30 0000087050 neond:StockOptionsAndWarrantsMember 2012-07-01 2012-09-30 0000087050 us-gaap:MinimumMember 2012-07-01 2012-09-30 0000087050 neond:CustomerOneMember 2012-07-01 2012-09-30 0000087050 neond:CustomerTwoMember 2012-07-01 2012-09-30 0000087050 neond:WarrantsOneMember 2012-07-01 2012-09-30 0000087050 neond:KoboMember 2012-07-01 2012-09-30 0000087050 neond:BarnesAndNobleMember 2012-07-01 2012-09-30 0000087050 2012-01-01 2012-09-30 0000087050 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000087050 country:US 2012-01-01 2012-09-30 0000087050 neond:OutsideOfUnitedStatesMember 2012-01-01 2012-09-30 0000087050 us-gaap:StockOptionsMember 2012-01-01 2012-09-30 0000087050 neond:StockOptionsAndWarrantsMember 2012-01-01 2012-09-30 0000087050 us-gaap:MinimumMember 2012-01-01 2012-09-30 0000087050 us-gaap:MaximumMember 2012-01-01 2012-09-30 0000087050 us-gaap:WarrantMember 2012-01-01 2012-09-30 0000087050 us-gaap:ConvertiblePreferredStockMember 2012-01-01 2012-09-30 0000087050 us-gaap:ConvertibleDebtSecuritiesMember 2012-01-01 2012-09-30 0000087050 us-gaap:SeriesAPreferredStockMember 2012-01-01 2012-09-30 0000087050 us-gaap:SeriesBPreferredStockMember 2012-01-01 2012-09-30 0000087050 us-gaap:CommonStockMember 2012-01-01 2012-09-30 0000087050 neond:CustomerOneMember 2012-01-01 2012-09-30 0000087050 neond:CustomerTwoMember 2012-01-01 2012-09-30 0000087050 neond:WarrantsOneMember 2012-01-01 2012-09-30 0000087050 neond:KoboMember 2012-01-01 2012-09-30 0000087050 us-gaap:ComputerEquipmentMember 2012-01-01 2012-09-30 0000087050 us-gaap:FurnitureAndFixturesMember 2012-01-01 2012-09-30 0000087050 neond:August2009EmployeeWarrantsMember 2012-01-01 2012-09-30 0000087050 neond:January2010InvestorWarrantMember 2012-01-01 2012-09-30 0000087050 neond:DebtExtensionWarrantsMember 2012-01-01 2012-09-30 0000087050 neond:September2010RepricingWarrantMember 2012-01-01 2012-09-30 0000087050 neond:October2010RepricingWarrantsMember 2012-01-01 2012-09-30 0000087050 neond:October2010EmployeeWarrantsMember 2012-01-01 2012-09-30 0000087050 neond:December2010EmployeeWarrantsMember 2012-01-01 2012-09-30 0000087050 neond:January2011EmployeeWarrantMember 2012-01-01 2012-09-30 0000087050 neond:February2011LegalAdvisorWarrantMember 2012-01-01 2012-09-30 0000087050 neond:March2011InvestorWarrantsMember 2012-01-01 2012-09-30 0000087050 neond:March2011InvestorWarrantsOneMember 2012-01-01 2012-09-30 0000087050 neond:May2011ConsultantWarrantMember 2012-01-01 2012-09-30 0000087050 neond:September2011EmployeeWarrantMember 2012-01-01 2012-09-30 0000087050 neond:NonEmployeeDirectorStockOptionPlanMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000087050 neond:NonEmployeeDirectorStockOptionPlanMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000087050 neond:NonOfficerStockOptionPlanAndEquityIncentivePlanMember us-gaap:MaximumMember 2012-01-01 2012-09-30 0000087050 neond:NonOfficerStockOptionPlanAndEquityIncentivePlanMember us-gaap:MinimumMember 2012-01-01 2012-09-30 0000087050 neond:VasakronanFastigheterAbOneMember 2012-01-01 2012-09-30 0000087050 neond:VasakronanFastigheterAbMember neond:AnnualMember 2012-01-01 2012-09-30 0000087050 neond:VasakronanFastigheterAbOneMember neond:MonthMember 2012-01-01 2012-09-30 0000087050 2012-09-30 0000087050 us-gaap:WarrantMember 2012-09-30 0000087050 country:US 2012-09-30 0000087050 us-gaap:StockOptionsMember 2012-09-30 0000087050 neond:StockOptionsAndWarrantsMember 2012-09-30 0000087050 us-gaap:SeriesAPreferredStockMember 2012-09-30 0000087050 us-gaap:SeriesBPreferredStockMember 2012-09-30 0000087050 neond:FutureLicenseFeesFromOneCustomerMember 2012-09-30 0000087050 us-gaap:CommonStockMember 2012-09-30 0000087050 neond:VasakronanFastigheterAbMember 2012-09-30 0000087050 neond:August2009EmployeeWarrantsMember 2012-09-30 0000087050 neond:January2010InvestorWarrantMember 2012-09-30 0000087050 neond:DebtExtensionWarrantsMember 2012-09-30 0000087050 neond:September2010RepricingWarrantMember 2012-09-30 0000087050 neond:October2010RepricingWarrantsMember 2012-09-30 0000087050 neond:October2010EmployeeWarrantsMember 2012-09-30 0000087050 neond:December2010EmployeeWarrantsMember 2012-09-30 0000087050 neond:January2011EmployeeWarrantMember 2012-09-30 0000087050 neond:February2011LegalAdvisorWarrantMember 2012-09-30 0000087050 neond:March2011InvestorWarrantsMember 2012-09-30 0000087050 neond:March2011InvestorWarrantsOneMember 2012-09-30 0000087050 neond:May2011ConsultantWarrantMember 2012-09-30 0000087050 neond:September2011EmployeeWarrantMember 2012-09-30 0000087050 country:SE 2012-09-30 0000087050 neond:DeferredEngineeringDevelopmentFeesFromFourMember 2012-09-30 0000087050 2012-11-09 0000087050 us-gaap:WarrantMember 2011-12-31 xbrli:shares iso4217:USD iso4217:USDxbrli:shares iso4217:EUR xbrli:pure neond:Customer neond:Contract neond:Plan neond:Option utr:sqft neond:Segment Neonode, Inc 0000087050 false --12-31 10-Q 2012-09-30 2012 Q3 Yes Smaller Reporting Company 33125319 12940000 11246000 3345000 1526000 234000 382000 16519000 13154000 108000 340000 16627000 13494000 447000 498000 601000 737000 1906000 1500000 2594000 2300000 2954000 3829000 2954000 3829000 33000 33000 142955000 146067000 13000 52000 -129328000 -136487000 13673000 9665000 16627000 13494000 2000000 444541 54425 1000000 444541 54425 0.001 0.001 0.001 0.001 83 114 83 95 83 114 83 95 0.001 0.001 0.001 0.001 848000000 70000000 70000000 70000000 0.001 0.001 32778993 33125319 32778993 33125319 1287000 2109000 1679000 4817000 333000 726000 337000 1080000 954000 1383000 1342000 3737000 385000 1043000 1451000 3616000 411000 1126000 920000 3437000 518000 2303000 1086000 3772000 1314000 4472000 3457000 10825000 -360000 -3089000 -2115000 -7088000 76000 211000 -1475000 -11043000 -1551000 -11254000 -1911000 -14343000 -2115000 -7088000 19000 30000 29000 71000 -1930000 -14373000 -2144000 -7159000 -0.07 -0.55 -0.06 -0.22 27934 26050 33021 32934 -34000 -16000 67000 39000 -1964000 -14389000 -2077000 -7120000 45000 517000 517000 606000 2957000 2957000 17000 68000 450000 -1841000 12000 135000 -205000 138000 2038000 688000 -1425000 -1602000 59000 290000 -59000 -290000 4228000 25000 491000 515000 155000 4718000 155000 1000 43000 3235000 -1694000 911000 4146000 12940000 11246000 90000 4000 71000 4228000 35000 120000 2860000 13379000 <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">1. Interim Period Reporting</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The unaudited interim condensed consolidated financial statements, include all adjustments, consisting of normal recurring adjustments that are, in the opinion of management, necessary for a fair presentation of the financial position and results of operations and cash flows for the interim periods. The results of operations for the three and nine months ended September 30, 2012 are not necessarily indicative of expected results for the full 2012 fiscal year.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The accompanying condensed consolidated financial statements as of September 30, 2012 and for the three and nine months ended September 30, 2012 and 2011 have been prepared by us, pursuant to the rules and regulations of the Securities and Exchange Commission (SEC). Certain information and footnote disclosures normally contained in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted.&#160;&#160;These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and notes contained in our consolidated financial statements and the notes thereto for the fiscal year ended December&#160;31, 2011.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Operations</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Neonode Inc., &#8220;we&#8221;, &#8220;us&#8221;, &#8220;our&#8221;, the &#8220;Company&#8221;, develops and licenses MultiSensing <font style="display: inline; font-size: 70%; vertical-align: text-top;">TM</font> touch user interfaces and optical multi-touch solutions. The cornerstone of our interface solutions is zForce&#174;, our patented touch technology. Neonode licenses the Neonode MultiSensing <font style="display: inline; font-size: 70%; vertical-align: text-top;">TM</font> touch technology to Original Equipment Manufacturers (&#8220;OEMs&#8221;) and Original Design Manufacturers (&#8220;ODMs&#8221;) who embed our technology into devices that they produce and sell. Our solution is currently being integrated into products such as mobile phones, e-Readers and tablets, printers and office equipment, toys and gaming consoles, automotive and in-vehicle infotainment systems.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;<font style="display: inline; font-weight: bold;">Intellectual Property</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We rely on a combination of intellectual property laws, as well as confidentiality procedures and contractual provisions, to protect our proprietary technology and our brand. We have registered, and applied for the registration of, U.S. and international trademarks, service marks, domain names, and copyrights. Additionally, we have filed U.S. and international patent applications covering certain of our proprietary technology. Over time, we have assembled a portfolio of patents, trademarks, service marks, copyrights, domain names, and trade secrets covering our products and services. Our proprietary technology is not dependent on any single patent or copyright or groups of related patents or copyrights. We believe the duration of our patents is adequate relative to the expected lives of our products. Although we rigorously protect our proprietary technology, any significant impairment of, or third-party claim against, our intellectual property rights could harm our business or our ability to compete.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">2.</font> <font style="display: inline; font-weight: bold;">Summary of Significant Accounting Policies</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Fiscal Year</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our fiscal year is the calendar year.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Principles of Consolidation</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and include the accounts of Neonode Inc. and its wholly owned Swedish subsidiary, Neonode Technologies AB. All inter-company accounts and transactions have been eliminated in consolidation.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;<font style="font-style: italic; display: inline; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></font></div> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"> <div > <div align="left" style="width: 100%;"><font style="display: inline; font-family: times new roman; font-size: 8pt;">&#160; </font></div> </div> </div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Estimates</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires making estimates and assumptions that affect, at the date of the financial statements, the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities, and the reported amounts of revenue and expenses during the reporting periods. Actual results could differ from these estimates. Significant estimates include, but are not limited to, collectability of accounts receivable, recoverability of long-lived assets, the valuation allowance related to our deferred tax assets&#160;and the fair value of securities, such as options and warrants issued for stock-based compensation.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Cash</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We have not had any liquid investments other than normal cash deposits with bank institutions to date.&#160; If in the future the Company purchases cash equivalents, the Company will consider all highly liquid investments with original maturities of three months of less to be cash equivalents.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Concentration of Cash Balance Risks</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cash balances are maintained at various banks in the U.S. and Sweden. At times, deposits held with financial institutions in the United States of America may exceed the amount of insurance provided by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;), which provides basic deposit coverage with limits up to $250,000 per owner. In addition to the basic insurance deposit coverage, the FDIC is providing temporary unlimited coverage for noninterest bearing transaction accounts through December 31, 2012. The Swedish government provides insurance coverage up to 100,000 Euro per customer and covers deposits in all types of accounts. The Company has not experienced any losses in such accounts and believes it is not exposed to any significant credit risk related to the deposits. As of September 30, 2012, the Company has approximately $10.8 million in excess of insurance limits.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Accounts Receivable and Allowance for Doubtful Accounts&#160;&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our accounts receivable are stated at net realizable value. Our policy is to maintain allowances for estimated losses resulting from the inability of our customers to make required payments. Credit limits are established through a process of reviewing the financial history and stability of each customer. Where appropriate, we obtain credit rating reports and financial statements of the customer when determining or modifying its credit limits. We regularly evaluate the collectability of our trade receivable balances based on a combination of factors.&#160;When a customer&#8217;s account balance becomes past due, we initiate dialogue with the customer to determine the cause. If it is determined that the customer will be unable to meet its financial obligation, such as in the case of a bankruptcy filing, deterioration in the customer&#8217;s operating results or financial position or other material events impacting its business, we record a specific allowance to reduce the related receivable to the amount we expect to recover. Should all efforts fail to recover the related receivable, we will write-off the account. We also record an allowance for all customers based on certain other factors including the length of time the receivables are past due and historical collection experience with customers.&#160;&#160;We determined that an allowance for doubtful accounts was not necessary at September 30, 2012 or December 31, 2011.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Debt Issuance Costs</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Debt issuance costs represent costs incurred in connection with the issuance of the convertible notes payable. Debt issuance costs are amortized over the term of the financing instrument on a straight-line basis, which approximates the effective interest method.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Property and Equipment</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. Depreciation and amortization are computed using the straight-line method based upon estimated useful lives of the assets ranging from three to five years as follows:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table style="font-size: 10pt; width: 50%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr bgcolor="#cceeff"> <td align="left" valign="top" width="28%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Computer equipment</font></div> </td> <td align="left" valign="top" width="15%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3 years</font></div> </td> </tr> <tr bgcolor="white"> <td align="left" valign="top" width="28%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Furniture and fixtures</font></div> </td> <td align="left" valign="top" width="15%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5 years</font></div> </td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Equipment purchased under capital leases is amortized on a straight-line basis over the estimated useful life of the asset or the term of the lease, whichever is shorter.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Upon retirement or sale of property and equipment, cost and accumulated depreciation and amortization are removed from the accounts and any gains or losses are reflected in the consolidated statement of operations. Maintenance and repairs are charged to expense as incurred.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Long-lived Assets</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We assess any impairment by estimating the future cash flow from the associated asset in accordance with relevant accounting guidance. If the estimated undiscounted future cash flow related to these assets decreases or the useful life is shorter than originally estimated, we may incur charges for impairment of these assets.&#160;&#160;At September 30, 2012, we believe there is no impairment of our long-lived assets. There can be no assurance, however, that market conditions will not change or sufficient commercial demand for our products and services will materialize, which could result in impairment of long-lived assets in the future.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Foreign Currency Translation and Transaction Gains and Losses</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The functional currency of our foreign subsidiary is the applicable local currency, the Swedish Krona. The translation from Swedish Krona to U.S. Dollars is performed for balance sheet accounts using current exchange rates in effect at the balance sheet date and for income statement accounts using a weighted-average exchange rate during the period. Gains or losses resulting from translation are included as a separate component of accumulated other comprehensive income (loss). Gains or (losses) resulting from foreign currency transactions are included in general and administrative expense in the accompanying condensed consolidated statements of operations and were $71,000 and $41,000 during the three months ended September 30, 2012 and 2011, respectively, and $82,000 and $(16,000) during the nine months ended September 30, 2012 and 2011, respectively. Foreign currency translation gain (loss) was $67,000 and $(34,000) for the three months ended September 30, 2012 and 2011, respectively, and was $39,000 and $(16,000) for the nine months ended September 30, 2012 and 2011, respectively.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="font-style: italic; display: inline; font-weight: bold;">Liability for Warrants and Embedded Derivatives</font> <font style="display: inline; font-weight: bold;">&#160;</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We do not enter into derivative contracts for purposes of risk management or speculation. &#160;However, from time to time, we enter into contracts that are not considered derivative financial instruments in their entirety but that include embedded derivative features, such as conversion features. Such embedded derivatives are assessed at inception of the contract and every reporting period, depending on their characteristics, are accounted for as separate derivative financial instruments pursuant to accounting guidance, if such embedded conversion features, if freestanding, would meet the classification of a liability. Accounting guidance requires that we analyze all material contracts and determine whether or not they contain embedded derivatives. Any such embedded conversion features that meet the above criteria are then bifurcated from their host contract and recorded on the consolidated balance sheet at fair value and the&#160;changes in the fair value of these derivatives are recorded each period in the consolidated statements of operations as an increase or decrease to non-cash charges for conversion features and warrants.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Similarly, if warrants meet the criteria in accordance with accounting guidance to be classified as liabilities, then the fair value of the warrants are recorded on the consolidated balance sheet at their fair values, and any changes in such fair values are recorded each period in the consolidated statements of operations as an increase or decrease to non-cash charges for conversion features.</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On December 14, 2011, all of the outstanding convertible debt and accrued interest was paid or converted into shares of the Company&#8217;s common stock. As of December 31, 2011, the fair value of the embedded conversion features was $0.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Concentration of Credit and Business Risks</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In the short term, we anticipate that we will depend on a limited number of customers for substantially all of our future revenue. Failure to anticipate or respond adequately to technological developments in our industry, changes in customer or supplier requirements or changes in regulatory requirements or industry standards, or any significant delays in the development or introduction of products or services, could have a material adverse effect on our business, operating results and cash flows.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our accounts receivable as of September 30, 2012 was due from eleven customers, three of which accounted for 77% of our accounts receivable as of September 30, 2012.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our net revenues for the three months ended September 30, 2012 was earned from nine customers. Our customers are located in the U.S., Europe and Asia. Customers who accounted for 10% or more of our net revenues during the three months ended September 30, 2012 are as follows:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify;"> <table style="font-size: 10pt; width: 100%; font-family: times new roman; text-align: justify;" cellspacing="0" cellpadding="0"> <tr style="text-align: justify;" valign="top"> <td align="right" style="width: 54pt;"> <div><font style="display: inline; font-size: 10pt;; font-family:symbol, serif"><font style="display: inline; font-family: times new roman;">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font></div> </td> <td> <div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Amazon - 31%</font></div> </td> </tr> </table> </div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr valign="top"> <td align="right" style="width: 54pt;"> <div><font style="display: inline; font-size: 10pt;; font-family:symbol, serif"><font style="display: inline; font-family: times new roman;">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font></div> </td> <td> <div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Kobo - 27%</font></div> </td> </tr> </table> </div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr valign="top"> <td align="right" style="width: 54pt;"> <div><font style="display: inline; font-size: 10pt;; font-family:symbol, serif"><font style="display: inline; font-family: times new roman;">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font></div> </td> <td> <div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Sony Corporation - 18%</font></div> </td> </tr> </table> </div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr valign="top"> <td align="right" style="width: 54pt;"> <div><font style="display: inline; font-size: 10pt;; font-family:symbol, serif"><font style="display: inline; font-family: times new roman;">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font></div> </td> <td> <div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Barnes &amp; Noble &#8211; 13%</font></div> </td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our net revenues for the nine months ended September 30, 2012 was earned from eighteen customers. Customers who accounted for 10% or more of our net revenues during the nine months ended September 30, 2012 are as follows:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr valign="top"> <td align="right" style="width: 54pt;"> <div><font style="display: inline; font-size: 10pt;; font-family:symbol, serif"><font style="display: inline; font-family: times new roman;">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font></div> </td> <td> <div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Amazon&#160;&#160;- 46%</font></div> </td> </tr> </table> </div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr valign="top"> <td align="right" style="width: 54pt;"> <div><font style="display: inline; font-size: 10pt;; font-family:symbol, serif"><font style="display: inline; font-family: times new roman;">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font></div> </td> <td> <div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Kobo &#8211; 16%</font></div> </td> </tr> </table> </div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr valign="top"> <td align="right" style="width: 54pt;"> <div><font style="display: inline; font-size: 10pt;; font-family:symbol, serif"><font style="display: inline; font-family: times new roman;">&#9679;</font>&#160;&#160;&#160;&#160;&#160;&#160;</font></div> </td> <td> <div align="justify" style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Sony Corporation &#8211; 14%</font></div> </td> </tr> </table> </div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our accounts receivable as of December 31, 2011 was due from five customers, two of which accounted for 87% of our accounts receivable as of December 31, 2011. Our net revenues for the three months ended September 30, 2011 was earned from six customers, three of which accounted for approximately 94% of our total net revenues for the three months ended September 30, 2011. Our net revenues for the nine months ended September 30, 2011 was earned from eight customers, three of which accounted for approximately 89% of our net revenues for the nine months ended September 30, 2011.</font></font></div> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Risks and Uncertainties</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our long-term success is dependent on our obtaining sufficient capital to fund our operations and to develop our products, and on our bringing such products to the worldwide market and obtaining sufficient sales volume to be profitable. To achieve these objectives, we may be required to raise additional capital through public or private financings or other arrangements. It cannot be assured that such financings will be available on terms attractive to us, if at all. Such financings may be dilutive to our stockholders and may contain restrictive covenants.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We are subject to certain risks common to technology-based companies in similar stages of development. Principal risks include risks relating to the uncertainty of market acceptance for our products, a history of losses since inception, our ability to remain competitive in response to new technologies, the costs to defend, as well as risks of losing patents and intellectual property rights, on our future customers ability to develop and sell products that incorporate our technology, the concentration of our operations in a limited number of facilities, the uncertainty of demand for our products in certain markets, our ability to manage growth effectively, our dependence on key members of our management and development team, our limited experience in conducting operations internationally, and our ability to obtain adequate capital to fund future operations.</font></div> <div style="text-indent: 0pt; display: block;">&#160;&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We are exposed to a number of economic and industry factors that could result in portions of our technology becoming obsolete or not gaining market acceptance. These factors include, but are not limited to, technological changes in our markets, our ability to meet changing customer requirements, competitive pressures in products and prices, and the ability of our customers to manufacture and sell their products that incorporate our technology.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">A significant portion of our business is conducted in currencies other than the U.S. dollar (the currency in which the Company&#8217;s financial statements are reported), primarily the Swedish Krona and, to a lesser extent, the Euro. We incur a significant portion of our expenses in Swedish Krona, including a significant portion of our product development expenses and a substantial portion of our general and administrative expenses. As a result, appreciation of the value of the Swedish Krona relative to the other currencies, particularly the U.S. dollar, could adversely affect operating results. We do not currently undertake hedging transactions to cover our currency exposure, but we may choose to hedge a portion of our currency exposure in the future as deemed appropriate.</font></font></div> </div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Our future success depends on market acceptance of our technology as well as our ability to introduce new versions of our technology to meet the evolving needs of our customers.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Revenue Recognition</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt;">Engineering Services:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We may sell engineering consulting services to our customers on a flat rate or hourly rate basis. We recognize revenue from these services when all of the following conditions are met: (1) evidence existed of an arrangement with the customer, typically consisting of a purchase order or contract; (2) our services were performed and risk of loss passed to the customer; (3) we completed all of the necessary terms of the contract; (4) the amount of revenue to which we were entitled was fixed or determinable; and (5) we believed it was probable that we would be able to collect the amount due from the customer. To the extent that one or more of these conditions has not been satisfied, we defer recognition of revenue.&#160;&#160;Generally, we recognize revenue as the engineering services stipulated under the contact are completed and accepted by our customers.&#160;&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; <font style="font-style: italic; display: inline;">&#160;</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 36pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt;">Licensing Revenues:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We also derive revenue from the licensing of internally developed intellectual property (&#8220;IP&#8221;). We enter into IP licensing agreements that generally provide licensees the right to incorporate our IP components in their products with terms and conditions that vary by licensee. The IP licensing agreements generally include a nonexclusive license for the underlying IP. Fees under these agreements may include license fees relating to our IP and&#160;royalties payable following the sale by our licensees of products incorporating the licensed technology. The license for our IP has standalone value and can be used by the licensee without maintenance and support. As of September 30, 2011, Neonode meets all the accounting requirements for revenue recognition as per unit royalty products are distributed or licensed by the Company&#8217;s customers.&#160;&#160;&#160;For technology license arrangements that do not require significant modification or customization of the underlying technology, we recognize new technology license revenue when: (1) we enter into a legally binding arrangement with a customer for the license of technology; (2) customer distributes or license the products; (3) customer payment is deemed fixed or determinable and free of contingencies or significant uncertainties; and (4) collection is reasonably assured.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Prior to September 30, 2011, we deferred the technology license fee revenue until such time as the warranty period stipulated in the license agreement expired because we did not have sufficient historical experience in estimating potential warranty costs.&#160; From June 2010 to September 30, 2011, we entered into 12 technology license contracts with customers.&#160; During that time there were no warranty related costs incurred for any customer products after they have been released to market.&#160; During the quarter ended September 30, 2011, the Company performed an analysis and determined that it had sufficient historical evidence regarding estimated warranty costs and therefore began recognizing technology license fee revenues, net of warranty costs, if any, as the products incorporating the Neonode technology are distributed or licensed by our customers, assuming all other revenue recognition criteria has been met.&#160; Our customers report to us the quantities of products distributed by them after the end of the reporting period stipulated in the contract, generally 30 to 45 days after the end of the month or quarter.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font>&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Explicit return rights are not offered to customers. There have been no returns through September 30, 2012.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt;">Hardware Products:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We may from time-to-time develop custom hardware products for our customers that incorporate our touchscreen technology. Our policy is to recognize revenue from hardware product sales when title transfers and risk of loss has passed to the customer, which is generally upon shipment of our hardware products to our customers. We will estimate expected sales returns and record the amount as a reduction of revenue and cost of hardware and other revenue at the time of shipment. To date, we have not sold any hardware products.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Software Products:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We may derive revenues from software licensing sales.&#160;&#160;We will account for the licensing of software in accordance with accounting guidance and such guidance requires judgment, including whether a software arrangement includes multiple elements, and if so, whether vendor-specific objective evidence (&#8220;VSOE&#8221;) of fair value exists for those elements.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For software license arrangements that do not require significant modification or customization of the underlying software, we will recognize new software license revenue when: (1) we enter into a legally binding arrangement with a customer for the license of software; (2) we deliver the products; (3) customer payment is deemed fixed or determinable and free of contingencies or significant uncertainties; and (4) collection is reasonably assured.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We allocate revenues to all deliverables based on their relative selling price using a specific hierarchy. The hierarchy is as follows: VSOE, third-party evidence of selling price (&#8220;TPE&#8221;) or best estimate of selling price (&#8220;BESP&#8221;).</font></font></div> </div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">When a sale involves multiple elements, we will allocate the entire fee from the arrangement to each respective element based on VSOE of fair value and recognize revenue when each element&#8217;s revenue recognition criteria are met. VSOE of fair value for each element is established based on the price charged when the same element is sold separately. We have established VSOE for our software licenses based on historical stand-alone sales to third parties or from the stated renewal rates contained in the customer contracts. Maintenance service revenue is recognized on a straight-line basis over the support period.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We have not yet demonstrated VSOE for the professional services that are rendered in conjunction with our software license sales. In accordance with the hierarchy we would attempt to establish the selling price of professional services using TPE. Our product contains significant differentiation such that the comparable pricing of products with similar functionality cannot be obtained. We are typically not able to obtain TPE for professional services.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">When we are unable to establish selling prices using VSOE or TPE, we use BESP. The objective of BESP is to determine the price at which we would transact a sale if professional services were sold on a stand-alone basis. BESP is generally used for offerings that are not typically sold on a stand-alone basis or for highly customized offerings.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We will also continue to defer revenues that represent undelivered post-delivery engineering support until the engineering support has been completed and the software product is accepted. To date, we have not sold any software products.</font></div> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;"> <div >&#160;</div> <div > <div align="right" style="width: 100%;"><font style="display: inline; font-family: times new roman; font-size: 8pt;">&#160; </font></div> </div> </div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt;">Deferred Revenue</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">From time-to-time the Company receives pre-payments from its customers related to future services or future license fee revenues. The Company defers these revenues until the services have been provided or until the license fees are earned.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Advertising</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Advertising costs are expensed as incurred. Advertising costs for the three and nine months ended September 30, 2012 and 2011 amounted to approximately $20,000 and $302,000, and $29,000 and $100,000, respectively.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Product Research and Development</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Research and development (&#8220;R&amp;D&#8221;) costs are expensed as incurred. R&amp;D costs consist mainly of personnel related costs in addition to some external consultancy costs such as testing, certifying and measurements.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Stock-Based Compensation Expense</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We measure the cost of employee services received in exchange for an award of equity instruments, including share options, based on the fair value of the award on the grant date, and recognize the value as compensation expense over the period the employee is required to provide services in exchange for the award, usually the vesting period, net of estimated forfeitures.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt;">&#160;</font>&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;We account for equity instruments issued to non-employees at their fair value and the unvested portion is re-measured each reporting period as long as the instrument requires variable accounting.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">When determining stock-based compensation expense involving options and warrants, we determine the estimated fair value of options and warrants using the Black-Scholes option pricing model.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Accounting for Debt Issued with Detachable Stock Purchase Warrants and Beneficial Conversion Features</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We account for debt issued with stock purchase warrants by allocating the proceeds of the debt between the debt and the detachable warrants based on the relative fair values of the debt security without the warrants and the warrants themselves, if the warrants are equity instruments.&#160;&#160;&#160;The relative fair value of the warrants are recorded as a debt discount and amortized to expense over the life of the related debt using the effective interest method. At each balance sheet date, we make a determination if these warrant instruments should be classified as liabilities or equity, and reclassify them if the circumstances dictate.&#160;&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In certain instances, the Company enters into convertible notes that provide for an effective or actual rate of conversion that is below market value, and the embedded conversion feature does not qualify for derivative treatment (a &#8220;BCF&#8221;).&#160;&#160;In these instances, we account for the value of the BCF as a debt discount, which is then amortized to expense over the life of the related debt using the straight-line method which approximates the effective interest method.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Income Taxes</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We recognize deferred tax liabilities and assets for the expected future tax consequences of items that have been included in the consolidated financial statements or tax returns. We estimate income taxes based on rates in effect in each of the jurisdictions in which we operate. Deferred income tax assets and liabilities are determined based upon differences between the financial statement and income tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. The realization of deferred tax assets is based on historical tax positions and expectations about future taxable income. Valuation allowances are recorded against net deferred tax assets when, in our opinion, realization is uncertain based on the &#8220;not more likely than not&#8221; criteria of the accounting guidance.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Based on the uncertainty of future pre-tax income, we fully reserved our net deferred tax assets as of September 30, 2012 and December 31, 2011. In the event we were to determine that we would be able to realize our deferred tax assets in the future, an adjustment to the deferred tax asset would increase income in the period such a determination was made. The provision for income taxes represents the net change in deferred tax amounts, plus income taxes payable for the current period.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We follow the relevant accounting guidance related to uncertain tax positions, which provisions include a two-step approach to recognizing, de-recognizing and measuring uncertain tax positions.&#160;&#160;As a result, we did not recognize a liability for unrecognized tax benefits.&#160;&#160;As of September 30, 2012 and December 31, 2011, we had no unrecognized tax benefits.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Net Loss Per Share</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Net loss per share amounts have been computed based on the weighted-average number of shares of common stock outstanding during the period. Net loss per share, assuming dilution amounts from common stock equivalents, is computed based on the weighted-average number of shares of common stock and potential common stock equivalents outstanding during the period. The weighted-average number of shares of common stock and potential common stock equivalents used in computing the net loss per share for three and nine months ended September 30, 2012 and 2011 exclude the potential common stock equivalents, as the effect would be anti-dilutive&#160;(See Note 10).</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Comprehensive Income (Loss)</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounting Standards Codification (&#8220;ASC&#8221;) Topic 220<font style="font-style: italic; display: inline;">, Comprehensive Income,</font> establishes standards for reporting and displaying comprehensive income (loss) and its components in the condensed consolidated financial statements. Accumulated other comprehensive income (loss) includes foreign currency translation gains or losses as a result of consolidation.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; <font style="font-style: italic; display: inline; font-weight: bold;">&#160;</font></font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Cash Flow Information</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cash flows in foreign currencies have been converted to U.S. dollars at an approximate weighted-average exchange rate for the respective reporting periods.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The weighted-average exchange rate for the consolidated statements of operations was 6.67 and 6.48 Swedish Krona to one U.S. Dollar for the three months ended September 30, 2012 and 2011, respectively. The weighted-average exchange rate for the condensed consolidated statements of operations was 6.79 and 6.41 Swedish Krona to one U.S. Dollar for the nine months ended September 30, 2012 and 2011, respectively. The exchange rate for the condensed consolidated balance sheets was 6.53 and 6.92 Swedish Krona to one U.S. Dollar as of September 30, 2012 and December 31, 2011, respectively.&#160;&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Fair Value of Financial Instruments</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We disclose the estimated fair values for all financial instruments for which it is practicable to estimate fair value. Financial instruments including cash and cash equivalents, accounts receivable, payables and accrued expenses are deemed to approximate fair value due to their short maturities.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">New Accounting Pronouncements</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In May 2011, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Updates (&#8220;ASU&#8221;) No.&#160;2011-4, <font style="font-style: italic; display: inline;">Fair Value Measurement</font> ("ASU 2011-04"). ASU 2011-04 amends existing guidance to achieve convergence in measurement and disclosure between U.S. GAAP and International Financial Reporting Standards ("IFRS"). ASU 2011-04 is effective for fiscal year 2012. The adoption of ASU 2011-04 did not impact the Company&#8217;s results of operations or its financial position.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In June 2011, the FASB issued ASU No. 2011-05, &#160; <font style="font-style: italic; display: inline;">Presentation of Comprehensive Income</font> (&#8220;ASU 2011-05&#8221;).&#160; The provisions of ASU 2011-05 allow an entity the option to present the total of comprehensive income (loss), the components of net income (loss), and the components of other comprehensive income (loss) either in a single continuous statement of comprehensive income (loss) or in two separate but consecutive statements.&#160; In both choices, an entity is required to present each component of net income (loss) along with total net income (loss), each component of other comprehensive income (loss) along with a total for other comprehensive income (loss), and a total amount for comprehensive income (loss).&#160; The statement(s) are required to be presented with equal prominence as the other primary financial statements.&#160; ASU No. 2011-05 eliminates the option to present the components of other comprehensive income (loss) as part of the statement of changes in stockholders&#8217; equity but does not change the items that must be reported in other comprehensive income (loss) or when an item of other comprehensive income (loss) must be reclassified to net income (loss).&#160; Certain provisions of ASU No. 2011-05 are effective for the Company&#8217;s interim reporting period beginning on or after December 15, 2011, with retrospective application required.&#160; The adoption of ASU No. 2011-05&#160;resulted in presentation changes to the Company&#8217;s consolidated statements of operations and the addition of separate consolidated statements of comprehensive income (loss).&#160; The adoption of ASU No. 2011-05 did not impact the Company&#8217;s results of operations or its financial position.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; <font style="display: inline; font-weight: bold;">&#160;</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">3.&#160;Convertible Debt</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Senior Convertible Secured Notes- 2007</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">At December 31, 2011, all of convertible promissory notes (&#8220;Senior Convertible Secured Notes-2007&#8221;) have been converted in shares of our common stock. The Senior Convertible Secured Notes &#8211; 2007 were originally due August 26, 2010. On September 22, 2010, we entered into a debt modification agreement with the two holders of an aggregate of $126,362 of convertible promissory notes that were due on August 26, 2010. Based on the terms of the modification, this transaction qualified as debt extinguishment accounting under the relevant accounting guidance. As part of the debt extinguishment, the maturity date of the convertible promissory notes was extended until April 26, 2011. We entered into a debt-for-equity repayment plan whereby we were retiring the convertible promissory notes in equal installments by issuing our common stock priced at a 15% discount from the average market closing price for the five days ending on the 25th of each month over the eight month period beginning September 26, 2010 ending on April 26, 2011.&#160;&#160;The holders of the notes had the right to convert the outstanding balance priced at $2.25 per share if the market value of our common stock is greater than $2.50 per share for five consecutive days.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the nine months ended September 30, 2011, we issued the note holders 31,570 shares of our common stock pursuant to the debt-for-equity repayment plan and retired the remaining note principal balance on April 26, 2011. We recorded $84,657 of note principal reduction and $1,054 of interest payment.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">September 2009 Senior Convertible Secured Notes Financing transaction</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the period from August 25, 2009 through December 15, 2009, we completed a private placement of convertible notes totaling $987,000 that were converted, at the holder&#8217;s option, into shares of our common stock at a conversion price of $0.50 per share (the &#8220;Convertible Notes - 2009&#8221;).&#160;&#160;The convertible note holders had the right to have the conversion price adjusted to equal the lower stock price if we issued common stock or convertible notes at a lower conversion price than $0.50 per share during the period that the notes were outstanding. The Convertible Notes - 2009 that were originally due on December 31, 2010 were extended to June 30, 2011 (see below under Warrant Repricing and Debt Extension Financing Transaction &#8211; 2010) and bore annual interest rate of 7%, payable on June 30 and December 31 of each year that the convertible notes were outstanding. In addition, we issued 986,983 three-year warrants to the convertible note holders with an exercise price of $1.00 per share. The warrants may be exercised and converted to common stock, at the warrant holder&#8217;s option, beginning on the six-month anniversary of the date of issuance until the warrant expiration date.&#160; <font style="display: inline;">As a result of the conversions and repayments during the nine months ended September 30, 2011, the Company reclassified approximately $4.6 million of the related derivative liabilities to additional paid-in capital. As of September 30, 2011, the fair value of the remaining embedded conversion features was $0 due to the repayment or conversion of all the Convertible Notes - 2009. The Company recorded a loss of $2.3 million due to the change in the fair value of the embedded conversion features of these Convertible Notes &#8211; 2009 during the nine months ended September 30, 2011.</font> As of September 30, 2011, all of the Convertible Notes &#8211; 2009 have been paid in full with cash or have been converted to shares of our common stock<font style="display: inline; font-family: times new roman;">.</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The embedded conversion feature of the Convertible Notes &#8211; 2009 met the definition of a derivative financial instrument and was classified as a liability in accordance with relevant accounting guidance. The note holders had the right to convert the debt into shares of our common stock, and the notes included price protection whereby these notes were protected for as long as the notes remained outstanding against future private placements made at lower share prices, and therefore, the total number of shares of our common stock that the convertible notes can be convertible into was not fixed. The embedded conversion features were revalued on each balance sheet date and marked-to-market with the change recorded to non-cash items related to debt discounts, deferred financing fees and the valuation of conversion features and warrants on the consolidated statements of operations.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the three and nine months ended September 30, 2011 we recorded a total of $0 and $15,000 in interest expense related to the principal balance of the Convertible Notes &#8211; 2009, respectively.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Senior Convertible Secured Notes- 2010</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the period from January through June 30, 2010, we received $1,597,000 in cash proceeds and converted $163,000 of accounts payable related to a private placement of convertible notes (the &#8220;Convertible Notes &#8211; 2010&#8221;) and stock purchase warrants that were convertible, at the holder&#8217;s option, into shares of our common stock at a conversion price of $0.50 per share and we issued 1,760,712 stock purchase warrants that had an exercise price of $1.00 per share. The convertible note holders had the right to have the conversion price adjusted to equal the lower stock price if we issued stock or convertible notes at a lower conversion price than $0.50 during the period that the notes were outstanding. These convertible notes were originally due on December 31, 2010 and were extended to June 30, 2011(see below under Warrant Repricing and Debt Extension Financing Transaction &#8211; 2010) and bore annual interest rate of 7%, payable on June 30 and December 31 of each year that the convertible notes were outstanding. The warrants may be exercised and converted to common stock, at the warrant holder&#8217;s option, beginning on the six-month anniversary date of issuance until the warrant expiration date. We are not obligated to register the common stock related to the convertible debt or the warrants. During the year ended December 31, 2011, we issued 3,557,171 shares of our common stock to holders of Convertible Notes &#8211; 2010 who converted principal of $1,750,143 and $28,442 of related accrued interest. As of December 31, 2011, all of the Convertible Notes &#8211; 2010 have been converted to shares of our common stock.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The embedded conversion feature of the convertible debt issued in the 2010 convertible debt financing transaction met the definition of a derivative financial instrument and was classified as a liability in accordance with accounting guidance. The note holders had the right to convert the debt into shares of our common stock, and the notes included price protection whereby these notes were protected for as long as the notes remain outstanding against future private placements made at lower share prices, and therefore, the total number of shares of our common stock that the convertible notes may be convertible into was not fixed. The embedded conversion features were revalued on each balance sheet date and marked to market with the increase or decrease included in fair value to non-cash items related to debt discounts and deferred financing fees and the valuation of conversion features and warrants on the condensed consolidated statements of operations. <font style="display: inline;">As a result of the conversions during the nine months ended September 30, 2011, the Company reclassified approximately $8.7 million of the related derivative liabilities to additional paid-in capital. As of September 30, 2011, all of the Convertible Notes &#8211; 2010 have been converted to shares of our common stock. As of September 30, 2011, the fair value of the remaining embedded conversion features is $0 as all the Convertible Notes &#8211; 2010 were converted. The Company recorded a loss of approximately $4.4 million due to the change in the fair value of the embedded conversion feature of these Convertible Notes &#8211; 2010 during the nine months ended September 30, 2011.</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the three and nine months ended September 30, 2011 we recorded a total of&#160;&#160;$0 and $28,000,&#160;respectively, in interest expense related to the principal balance of the Convertible Notes &#8211; 2010.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Senior Convertible Secured Notes- 2011</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In March 2011, we received $3.7 million in cash proceeds and commitments for an additional $491,000 related to a private placement of convertible notes, bearing interest at a rate of seven percent (7%) per annum, that matured on March 1, 2014, and that could be converted at the holder&#8217;s option into 1,691,320 shares of our common stock at a conversion price of $2.50 per share (the &#8220;Convertible Secured Notes &#8211; 2011&#8221;). The Company received the $491,000 in cash proceeds related to the unpaid commitments in April and May 2011. The notes would automatically be converted into shares of the Company&#8217;s common stock in the event that on or before the note due date either (a) the Company&#8217;s common stock is traded at a price per share of $6.25 or higher for five (5) consecutive trading days, or (b) the Company consummates a financing in the amount of at least $5 million.&#160;&#160;In the event that the loan principal and accrued interest was not repaid by the Company by the due date, and the investor has not previously converted the note, the investor&#8217;s sole remedy for such non-payment shall be the payment of additional annual interest at a rate of 10% per year.&#160;&#160;The accrued interest was payable in stock, using the $2.50 conversion price, or cash, at the holder&#8217;s option, on June 30 and December 31 of each year.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In addition,&#160;&#160;as of March 31, 2011, the Company issued 373,730 new five-year common stock purchase warrants, with an exercise price of $3.13 per share (the &#8220;March 2011 Warrants&#8221;), with each investor receiving a number of March 2011 Warrants that was equal&#160;&#160;to twenty-five percent (25%) of the investor&#8217;s note to the Company.&#160;&#160;The Company issued an additional 49,100 warrants in April 2011 related to the collection of the payment totaling $491,000. The March 2011 Warrants may be exercised by cash payment or through cashless exercise by the surrender of warrant shares having a value equal to the exercise price of the portion of the warrants being exercised.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In connection with the March 2011 financing transaction the Company valued the warrants issued to the convertible note holders on a relative fair value basis using the Black-Scholes option pricing model, totaling $813,000. This relative fair value of the warrants was recorded as a debt discount. The embedded conversion features to the notes was determined to meet the definition of a derivative liability and as of the date of issuance was valued at $4.1 million. In accordance with relevant accounting guidance, the Company recorded an additional debt discount ($2.9 million) up to the full amount of the notes, recorded the derivative liability for the embedded conversion feature at $4.1 million and recorded the fair value in excess of face amount of debt as interest expense on the issuance date of $1.2 million. The debt discount was amortized in full upon the conversion of the notes to common stock on December 14, 2011. As of December 31, 2011, the fair value of the embedded conversion feature was $0 due to the conversion of all the Senior Convertible Secure Notes &#8211; 2011.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="margin-left: 36pt;"></font>On June 30, 2011, the Company issued 27,851 shares of unregistered common stock to note holders of the Senior Convertible Secured Notes &#8211; 2011 private placement financing transaction in lieu of cash for their $69,628 accrued interest payment that was due June 30, 2011. In addition, the Company paid $10,277 of the accrued interest in cash to note holders who declined to convert their interest payment to stock.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of September 30, 2011, the fair value of the embedded conversion feature was $7.6 million and as such, the Company recorded a loss on the change in fair value of the embedded conversion feature of $1.5 million and $2.8 million for the three and nine months ended September 30, 2012, respectively, which is included in the accompanying consolidated condensed statement of operations as a component on non-cash items related to debt discounts, deferred financing fees and valuation of conversion features and warrants.</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In October and November 2011, note holders of $575,000 of the original $4.2 million Senior Convertible Secure Notes &#8211; 2011 exercised their right to convert their notes and accrued interest and were issued 232,125 shares of our common stock.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On December 13, 2011, following a public offering pursuant to a Registration Statement on Form S-3, the Company received gross proceeds in excess of $5 million. Pursuant to the terms, as defined, in the Senior Convertible Secure Notes &#8211; 2011 agreements, the remaining outstanding principal balance&#160;plus accrued interest, was automatically converted into shares of common stock at a conversion price of $2.50 per share. In accordance with the terms of the agreement, the Company automatically converted approximately $3.7 million of remaining principal and approximately $130,000 of accrued interest into 1,513,237 shares of the Company&#8217;s common stock. In addition, the Company issued 99,461 shares of common stock related to the bonus interest feature associated with the mandatory conversion of the debt. As of December 31, 2011, the fair value of the embedded conversion features was $0. As of December 31, 2011, all of the Senior Convertible Secure Notes - 2011 plus accrued interest was paid or converted into shares of common stock.&#160;&#160;</font></div> </div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">4.</font> <font style="display: inline; font-weight: bold;">Stockholders&#8217; Equity</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On February 29, 2012, the Company filed a Certificate of Correction with the Secretary of State of Delaware effectively reducing the amount of its authorized shares from 848,000,000 shares of Common Stock and 2,000,000 shares of Preferred Stock to 70,000,000 shares of Common Stock and 1,000,000 shares of Preferred Stock. This reflects the new capital structure of the Company following its 1-for-25 reverse split that became effective at the close of business on March 25, 2011.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On May 1, 2012, the Company began trading its common stock on the NASDAQ Stock Market Capital Markets under trading symbol NEON.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt;">Common Stock</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On March 16, 2012, John Reardon, a member of our board of directors, exercised a warrant to purchase 200,000 shares of common stock using the net exercise provision allowed in the warrant and received 174,798 shares of our common stock.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the nine months ended September 30, 2012, Series B Preferred stockholders exchanged 19 shares of Series B Preferred stock for 2,509 shares of our common stock.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;During the nine months ended September 30, 2012, warrant holders (excluding members of our board of directors) exercised warrants to purchase 116,000 shares of common stock using the net exercise provision allowed in the warrant and received 79,050 shares of our common stock. Warrant holders exercised warrants to purchase 17,500 shares of common stock and paid a cash exercise price of $3.13 per share for a total exercise price of $54,775. In addition, a warrant holder exercised a warrant to purchase 72,469 shares of common stock and paid a cash exercise price of $1.38 per share for a total exercise price of $100,007.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt;">Preferred Stock</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The terms of the Series A and Series B Preferred stock are as follows:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div align="left" style="text-align: justify;"> <table style="font-size: 10pt; width: 100%; font-family: times new roman; text-align: justify;" cellspacing="0" cellpadding="0"> <tr style="text-align: justify;"> <td valign="top" width="7%"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman;">&#9679;</font></div> </td> <td align="left" valign="top" width="93%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Dividends and Distributions.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td align="left" valign="top" width="7%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="top" width="20%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Series A Preferred:</font></div> </td> <td style="text-align: justify;" valign="top" width="73%"> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The holders of shares of Series A Preferred stock are entitled to participate with the holders of our common stock with respect to any dividends declared on the common stock in proportion to the number of shares of common stock issuable upon conversion of the shares of Series A Preferred stock held by them.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td align="left" valign="top" width="5%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="top" width="15%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Series B Preferred:</font></div> </td> <td style="text-align: justify;" valign="top" width="54%"> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The holders of shares of Series B Preferred stock are entitled to participate with the holders of our common stock with respect to any dividends declared on the common stock in proportion to the number of shares of common stock issuable upon conversion of the shares of Series B Preferred stock held by them.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font>&#160;</div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td valign="top" width="7%"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman;">&#9679;</font></div> </td> <td align="left" valign="top" width="93%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Liquidation Preference.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td align="left" valign="top" width="7%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="top" width="20%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Series A Preferred:</font></div> </td> <td style="text-align: justify;" valign="top" width="73%"> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In the event of any liquidation, dissolution, or winding up of our operations, either voluntary or involuntary, subject to the rights of any other series of Preferred stock to be established by the Board of Directors (the &#8220;Senior Preferred Stock&#8221;), the holders of Series A Preferred stock shall be entitled to receive, after any distribution to the holders of Senior Preferred Stock and prior to and in preference to any distribution to the holders of common stock, $0.001 for each share of Series A Preferred stock then outstanding.</font></div> </td> </tr> </table> </div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td align="left" valign="top" width="7%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="top" width="20%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Series B Preferred:</font></div> </td> <td style="text-align: justify;" valign="top" width="73%"> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">In the event of any liquidation, dissolution, or winding up of our operations, either voluntary or involuntary, subject to the rights of the Series A Preferred stock and Senior Preferred Stock, the holders of Series B Preferred stock shall be entitled to receive, after any distribution to the holders of Senior Preferred Stock and prior to and in preference to any distribution to the holders of common stock, $0.001 for each share of Series B Preferred stock then outstanding.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td valign="top" width="7%"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman;">&#9679;</font></div> </td> <td align="left" valign="top" width="93%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Voting.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The holders of shares of Series A Preferred stock and Series B Preferred stock shall have one vote for each share of Series A Preferred stock and Series B Preferred stock held by them.</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td valign="top" width="7%"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman;">&#9679;</font></div> </td> <td align="left" valign="top" width="93%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Conversion.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Initially, each share of Series A Preferred stock and each share of Series B Preferred stock was convertible into one share of our common stock.&#160;&#160;Any modification to the conversion rate requires shareholder approval (see below). On March 31, 2009, our shareholders approved a resolution to increase the authorized share capital, and to increase the conversion ratio to 480.63 shares of common stock for each share of Series A Preferred stock and to 132.07 shares of our common stock for each shares of Series B Preferred stock, thus completing the restructuring begun in December 2008.&#160;&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Conversion of Preferred Stock Issued to Common Stock</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On April 24, 2009, we initiated the process of allowing the shareholders of our preferred stock to convert the Series A and B Preferred stock to shares of our common stock. In order to convert the preferred stock to common stock each preferred stock shareholder is required to submit the preferred stock certificate to our transfer agent and request conversion to common stock. The conversion to common stock is not mandatory and shareholders who own preferred stock may choose not to convert their preferred stock to shares of our common stock.&#160;&#160;The following table summarizes the Preferred stock not yet converted as of September 30, 2012.</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left"> <table style="font-size: 10pt; width: 100%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares of Preferred Stock Not Exchanged as of September 30, 2012</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Conversion Ratio</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares of Common Stock after Conversion of all Outstanding Shares of Preferred Stock Not yet Exchanged at September 30, 2012</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Series A Preferred stock</font></div> </td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">83</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">480.63</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">39,892</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="white"> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Series B Preferred stock</font></div> </td> <td align="right" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">95</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; padding-bottom: 2px;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">132.07</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">12,547</font></td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Total&#160;&#160;Remaining Not Exchanged</font></div> </td> <td align="right" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">178</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right; padding-bottom: 4px;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">52,439</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" nowrap="nowrap" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-size: 10pt; font-weight: bold;">5.</font><font style="display: inline; font-size: 10pt;">&#160;</font><font style="display: inline; font-size: 10pt; font-weight: bold;">Fair Value Measurement of Assets and Liabilities</font></font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left" style="text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Accounting guidance defines fair value, establishes a framework for measuring fair value, and expands disclosure requirements about fair value measurements. The accounting guidance does not mandate any new fair-value measurements and is applicable to assets and liabilities that are required to be recorded at fair value under other accounting pronouncements.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The three levels of the fair-value hierarchy are described as follows:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level&#160;1: Quoted prices (unadjusted) in active markets for identical assets and liabilities. As of September 30, 2012 and December 31, 2011, we had no level 1 assets or liabilities.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level&#160;2: Inputs other than Level&#160;1 that are observable, either directly or indirectly. As of September 30, 2012 and December 31, 2011, we had no level 2 assets or liabilities.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Level&#160;3: Inputs other than Level&#160;1 that are observable, either directly or indirectly. As of September 30, 2012 and December 31, 2011, we had no level 3 assets or liabilities.</font><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;<a name="fis_unidentified_table_5"></a></font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div align="left" style="margin-left: 36pt;"> <table style="font-size: 10pt; width: 90%; font-family: times new roman;" cellspacing="0" cellpadding="0"> <tr> <td align="left" valign="bottom" width="78%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="11%"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the Nine</font></div> </td> </tr> <tr> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="78%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="11%"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Months Ended</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30, 2011</font></div> </td> </tr> <tr> <td align="left" valign="bottom" width="78%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="10%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="bottom" width="78%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Annual dividend yield</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></div> </div> </td> </tr> <tr bgcolor="white"> <td valign="bottom" width="78%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Expected life (years)</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.08 &#8211; 3.0</font></div> </div> </td> </tr> <tr bgcolor="#cceeff"> <td valign="bottom" width="78%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Risk-free interest rate</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.08%- 1.27%</font></div> </div> </td> </tr> <tr bgcolor="white"> <td valign="bottom" width="78%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Expected volatility</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">110% - 263%</font></div> </div> </td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The assumptions above were used to value warrants granted to employees and consultants as well as the embedded conversion features associated with convertible debt for the nine months ended September 30, 2011.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On December 14, 2011, all of the outstanding convertible debt and accrued interest was paid or converted into shares of the Company&#8217;s common stock. As of December 31, 2011, the fair value of the embedded conversion features was $0.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">6.&#160;Deferred Revenue</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Engineering development fees are recorded as deferred revenue until such time as the engineering services have been provided.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of September 30, 2012 and December 31, 2011, we have $2.3 million and $1.5 million, respectively, of deferred license fee revenue related to a prepayment for future license fees from one customer and a total of $0.3 million and $0.4 million, respectively, of deferred engineering development fees from four customers, respectively. We are deferring the engineering development fee revenue until such time as the engineering work has been completed.</font></font></div> </div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-weight: bold;">7.</font> <font style="display: inline; font-weight: bold;">Stock-Based Compensation</font></font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We have three approved stock option plans for which stock options and restricted stock awards are available to grant to employees, consultants and directors. All employee and director stock options granted under our stock option plans have an exercise price equal to the market value of the underlying common stock on the grant date. There are no vesting provisions tied to performance conditions for any options, as vesting for all outstanding option grants was based only on continued service as an employee, consultant or director. All of our outstanding stock options and restricted stock awards are classified as equity instruments.</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="font-style: italic; display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Stock Options</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">As of September 30, 2012, we had two equity incentive plans:</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify;"> <table style="text-align: justify; width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr style="text-align: justify;"> <td align="left" valign="top" width="3%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="top" width="4%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160; <font style="display: inline; font-family: times new roman;">&#9679;</font></font></div> </td> <td style="text-align: justify;" valign="top" width="89%"> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The 1998 Non-Officer Stock Option Plan (the 1998 Plan), which expired in June 2008 ;</font></div> </td> </tr> <tr> <td align="left" valign="top" width="3%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="top" width="4%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline; font-family: times new roman;">&#9679;</font></font></div> </td> <td align="left" valign="top" width="89%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The 2006 Equity Incentive Plan (the 2006 Plan). &#160;</font></div> </td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We also had one non-employee director stock option plan as of September 30, 2012:</font></div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div> <table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" valign="top" width="3%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="top" width="4%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;<font style="display: inline; font-family: times new roman;">&#9679;</font></font></div> </td> <td style="text-align: justify;" valign="top" width="89%"> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The 2001 Non-Employee Director Stock Option Plan (the Director Plan), which expired in March 2011.</font></div> </td> </tr> </table> </div> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">A summary of the combined activity under all of the stock option plans is set forth below:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="left"> <table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="66%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Number of Options Outstanding</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted Average Exercise Price</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="66%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding at January 1, 2012</font></div> </td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">19,324</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">92.19</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="66%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Granted</font></div> </td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,505,000</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4.29</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="66%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Cancelled or expired</font></div> </td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(8,124</font></div> </td> <td align="left" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)&#160;</font></div> </td> <td align="right" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">69.36</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="white"> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="66%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Exercised</font></div> </td> <td align="right" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 2px solid;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 2px solid;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">---</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 2px solid;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 2px solid;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">---</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="66%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding at September 30, 2012</font></div> </td> <td align="right" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1,516,200</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5.06</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table style="width: 80%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" valign="bottom" width="68%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="11%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">For the Nine</font></div> </td> </tr> <tr> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="68%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="11%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Months Ended</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30, 2012</font></div> </td> </tr> <tr> <td align="left" valign="bottom" width="68%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="10%" colspan="2"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td valign="bottom" width="68%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Annual dividend yield</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></div> </div> </td> </tr> <tr bgcolor="white"> <td valign="bottom" width="68%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Expected life (years)</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times">3.85</font></div> </div> </td> </tr> <tr bgcolor="#cceeff"> <td valign="bottom" width="68%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Risk-free interest rate</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.43% - 0.58%</font></div> </div> </td> </tr> <tr bgcolor="white"> <td valign="bottom" width="68%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;Expected volatility</font></div> </div> </td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td valign="bottom" width="9%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">177% - 186%</font></div> </div> </td> </tr> </table> </div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The assumptions above were used to value stock options granted to employees and directors during the nine months ended September 30, 2012.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The aggregate intrinsic value of the 1,516,200 stock options that are outstanding, vested and expected to vest at September 30, 2012 is $0.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The 1998 Plan terminated effective June 15, 2008 and the Director Plan terminated effective March 2011. Although we can no longer issue stock options out of the plans, the outstanding options at the date of termination will remain outstanding and vest in accordance with their terms. Options granted under the Director Plan vested over a one to four-year period, expire five to seven years after the date of grant and have exercise prices reflecting market value of the shares of our common stock on the date of grant. Stock options granted under the 1998 and 2006 Plans are exercisable over a maximum term of ten years from the date of grant, vest in various installments over a one to four-year period and have exercise prices reflecting the market value of the shares of common stock on the date of grant.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the three and nine months ended September 30, 2011, the Company recorded $17,000 and $87,000, respectively, of stock option expense related to the vesting of stock options.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We did not grant any options to purchase shares of our common stock to employees or members of our Board of Directors (Board) during the nine months ended September 30, 2011.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the three and nine months ended September 30, 2012, we granted&#160;&#160;45,000 and 1,145,000 options to purchase shares of our common stock to employees and&#160;&#160;0 and 360,000 options to purchase shares of our common stock to members of our Board. The options have a 7-year life and 1/3 of the options are vested on the date of grant with the remaining to vest monthly over the remaining 24-months. During the three and nine months ended September 30, 2012, we recorded approximately $572,000 and $2.9 million, respectively, of stock based compensation expense related to vesting of such options.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Warrants</font></div> <div style="text-align: justify; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On December 3, 2010, we issued 120,000 warrants at an exercise price of $1.625 per share to an employee. The fair value of the warrants was $198,000 on the date of grant, using the Black-Scholes option pricing model, which is to be amortized over 24 months. During the nine months ended September 30, 2012 and 2011, we recorded $25,000 and $74,000, respectively, of stock based compensation expense related to vesting of such warrants.</font></font></div> </div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">We issued 80,000 five-year stock purchase warrants at an exercise price of $2.50 per share to our legal advisor during the nine months ended September 30, 2011. We also issued 20,000 three-year stock purchase warrants at an exercise price of $2.00 per share in one of our US based employees during the nine months ended September 30, 2011. In addition, we issued 20,000 shares three-year stock purchase warrants at an exercise price of $4.05 per share to an engineering consultant during the nine months ended September 30, 2011. The warrants to purchase an aggregate of 120,000 shares of our common stock vested on the date of the grant. The vested warrant granted to our legal advisor has a fair value on the grant of $193,000 and is included in general and administrative expense for the nine months ended September 30, 2011. The vested warrant granted to our employee has a fair value on the date of the grant of $37,000 and is included in product research and development expense for the nine months ended September 30, 2011. The vested warrant granted to our engineering consultant has a fair value on the date of grant of $73,000 and is included in product research and development expense for the nine months ended September 30, 2011.</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On April 25, 2011, Davisa Ltd. exercised warrants to purchase 50,000 shares of common stock. The Company recorded an additional $50,000 as stock based compensation to compensate Davisa Ltd. by waiving the $1.00 exercise price, and issued 50,000 shares of our common stock to Davisa Ltd. for services provided for the private placement of convertible notes and warrants in the March 2011 financing transaction.</font></font></div> </div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On September 12, 2011, we issued 20,000 warrants at an exercise price of $3.90 per share to an employee. The fair value of the warrants was $75,000 on the date of grant, using the Black-Scholes option pricing model, which is to be amortized over 24 months. During the three months ended September 30, 2012 and 2011 we recorded $9,000 and $2,000, respectively, of stock based compensation expense related to vesting of such warrants. During the nine months ended September 30, 2012 and 2011 we recorded $28,000 and $2,000, respectively, of stock based compensation expense related to vesting of such warrants.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The stock-based compensation expense reflects the fair value of the vested portion of options and warrants for the recipients at the date of issuance plus the amortization of the unvested portion of the stock options and warrants. Stock-based compensation expense related to stock options and warrants in the accompanying consolidated statements of operations is as follows (in thousands):</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;" >&#160;</div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div align="center"> <table style="width: 90%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="66%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Three months ended</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30, 2011</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" width="10%" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Three months ended</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30, 2012</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td style="padding-bottom: 4px;" valign="bottom" width="66%"> <div style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Stock-based compensation</font></div> </div> </td> <td style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">45</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="border-bottom: black 4px double; text-align: left;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="border-bottom: black 4px double; text-align: right;" valign="bottom" width="9%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">606</font></td> <td style="text-align: left; padding-bottom: 4px;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> </table> </div> <div align="justify" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><a name="fis_unidentified_table_7"></a></div> <div align="left"> <table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" style="padding-bottom: 4px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 4px double;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Nine months ended</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30, 2011</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 4px double;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Nine months ended</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30, 2012</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 4px double;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Remaining unamortized expense at</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 30, 2012</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Stock-based compensation</font></div> </td> <td style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">517</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,957</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3,222</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> </table> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The remaining unamortized expense related to stock options and warrants will be recognized on a straight line basis monthly as compensation expense over the remaining vesting period which approximates 1.7 years.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">See Note 5 for assumptions used to value warrants during the three and nine months ended September 30, 2011.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">A summary of all warrant activity is set forth below:</font></div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-indent: 0pt; display: block;"> <div align="left"> <table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="10"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">September 30, 2012</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr> <td align="left" style="padding-bottom: 2px;" valign="bottom"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding and exercisable</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Warrants</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted Average Exercise Price</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td style="border-bottom: black 2px solid; text-align: center; text-indent: 0pt; margin-left: 0pt; margin-right: 0pt;" valign="bottom" colspan="2"> <div style="text-align: center; text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Weighted Average Remaining Contractual Life</font></div> </td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">January 1, 2012</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">5,405,606</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.57</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">3.56</font></div> </td> <td align="left" valign="top" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;Issued</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></div> </td> <td align="left" valign="top" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;Expired/forfeited</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(62,384</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.25</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></div> </td> <td align="left" valign="top" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="white"> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;&#160;&#160;Exercised</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 2px solid;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 2px solid;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">(343,817</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">)</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 2px solid;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" style="border-bottom: black 2px solid;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.03</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 2px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 2px solid;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 2px solid;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">--</font></div> </td> <td align="left" style="padding-bottom: 2px;" valign="top" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="64%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">Outstanding and exercisable, September 30, 2012</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,999,405</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></div> </td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.60</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="padding-bottom: 4px;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" style="border-bottom: black 4px double;" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="right" style="border-bottom: black 4px double;" valign="bottom" width="9%"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.63</font></div> </td> <td align="left" style="padding-bottom: 4px;" valign="top" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> </table> </div> </div> <div style="text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">On March 16, 2012, John Reardon, a member of our board of directors, exercised a warrant to purchase 200,000 shares of common stock using the net exercise provision allowed in the warrant and received 174,798 shares of our common stock.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">During the nine months ended September 30, 2012, warrant holders (excluding members of our board of directors) exercised warrants to purchase 116,000 shares of common stock using the net exercise provision allowed in the warrant and received 79,050 shares of our common stock. Warrant holders exercised warrants to purchase 17,500 shares of common stock and paid a cash exercise price of $3.13 per share for a total exercise price of $54,775. In addition, a warrant holder exercised a warrant to purchase 72,469 shares of common stock and paid a cash exercise price of $1.38 per share for a total exercise price of $100,007.</font></div> <div style="text-align: justify; text-indent: 0pt; display: block;">&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">The fair value of stock-based awards to employees and directors is calculated using the Black-Scholes option pricing model, even though this model was developed to estimate the fair value of freely tradable, fully transferable options without vesting restrictions, which differ significantly from our stock options. The Black-Scholes model also requires subjective assumptions, including future stock price volatility and expected time to exercise, which greatly affect the calculated values. The expected term and forfeiture rate of options granted is derived from historical data on employee exercises and post-vesting employment termination behavior, as well as expected behavior on outstanding options. The risk-free rate is based on the U.S. Treasury rates in effect during the corresponding period of grant. The expected volatility is based on the historical volatility of our stock price. These factors could change in the future, which would affect fair values of stock options granted in such future periods, and could cause volatility in the total amount of the stock-based compensation expense reported in future periods.</font></div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font>&#160;</div> <div style="text-align: justify; text-indent: 36pt; display: block; margin-left: 0pt; margin-right: 0pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;"></font></font> <div> <table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td valign="bottom" width="84%" colspan="11"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 23.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Below is a summary of Outstanding Warrants to Purchase</font></div> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 23.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Common Stock as of September 30, 2012:</font></div> </td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> </tr> </table> <div>&#160;</div> <div align="left"> <table style="width: 100%; font-family: times new roman; font-size: 10pt;" cellspacing="0" cellpadding="0"> <tr> <td align="left" style="border-bottom: black 2px solid;" valign="bottom"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 1.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Description</font></div> </td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 2.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Issue&#160;Date</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Exercise Price</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 2.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Shares</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="padding-bottom: 2px;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> <td style="border-bottom: black 2px solid;" valign="bottom" colspan="2"> <div align="center" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 3.6pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">Expiration Date</font></div> </td> <td style="text-align: left; padding-bottom: 2px;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt; font-weight: bold;">&#160;</font></td> </tr> <tr> <td align="left" valign="bottom" width="52%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160; </font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%">&#160;</td> <td style="text-align: right;" valign="bottom" width="9%">&#160;</td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%">&#160;</td> <td style="text-align: right;" valign="bottom" width="9%">&#160;</td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%">&#160;</td> <td style="text-align: right;" valign="bottom" width="9%">&#160;</td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="left" valign="bottom" width="1%"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom" width="1%">&#160;</td> <td style="text-align: right;" valign="bottom" width="9%">&#160;</td> <td style="text-align: left;" valign="bottom" width="1%" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">August 2009 Employee Warrants</font></div> </td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8/25/2009</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">0.50</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">240,000</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">8/25/2016</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">January 2010 Investor Warrant</font></div> </td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1/28/2010</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.00</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">40,000</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1/28/2013</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2007 Debt Extension Warrants</font></div> </td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9/22/2010</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.00</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">16,000</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9/22/2015</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="white"> <td align="left" valign="bottom"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">September 2010 Repricing Warrant</font></div> </td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9/28/2010</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.38</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">4,000</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">9/28/2013</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> </tr> <tr bgcolor="#cceeff"> <td align="left" valign="bottom"> <div align="left" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">October 2010 Repricing Warrants</font></div> </td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; margin-left: 0pt; margin-right: 0.8pt;"><font style="display: inline; font-family: times new roman; font-size: 10pt;">10/18/2010</font></div> </td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">$</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">1.38</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: left;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td style="text-align: right;" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">2,312,362</font></td> <td style="text-align: left;" valign="bottom" nowrap="nowrap"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom"><font style="display: inline; font-family: times new roman; font-size: 10pt;">&#160;</font></td> <td align="right" valign="bottom" colspan="2"> <div align="right" style="text-indent: 0pt; display: block; mar